WO2003084532A1 - Analogues d'acide lipoique utiles en tant que provitamines et antioxydants - Google Patents

Analogues d'acide lipoique utiles en tant que provitamines et antioxydants Download PDF

Info

Publication number
WO2003084532A1
WO2003084532A1 PCT/US2002/010761 US0210761W WO03084532A1 WO 2003084532 A1 WO2003084532 A1 WO 2003084532A1 US 0210761 W US0210761 W US 0210761W WO 03084532 A1 WO03084532 A1 WO 03084532A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
acyl
ring
acid
skin
Prior art date
Application number
PCT/US2002/010761
Other languages
English (en)
Inventor
Mitchell A. Avery
Harrihar Pershadsingh
Original Assignee
Avery Mitchell A
Harrihar Pershadsingh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avery Mitchell A, Harrihar Pershadsingh filed Critical Avery Mitchell A
Priority to AU2002254546A priority Critical patent/AU2002254546A1/en
Priority to PCT/US2002/010761 priority patent/WO2003084532A1/fr
Publication of WO2003084532A1 publication Critical patent/WO2003084532A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • ⁇ -lipoic acid (thioctic acid, l,2-dithiacyclopentane-3 -valeric acid, l,2-dithiolane-3- pentanoic acid) is widely distributed in plants and animals in the form of the R-enantiomer; it acts as coenzyme in many enzymatic reactions, constitutes a growth factor for a number of bacteria and protozoa and is used in death-head fungus poisoning.
  • Lipoic acid (l,2-dithiolane-3 -pentanoic acid) is a naturally occurring compound. It is a component of mitochondrial multienzyme complexes which dehydrogenates ⁇ -keto acids (e.g. pyruvate).
  • lipoic acid is applied in the treatment of diabetic polyneuropathy, liver cirrhosis and metal intoxications. Particularly in diabetic polyneuropathy, the antioxidant activity of lipoic acid is considered to contribute to its therapeutic effect.
  • One aspect of this invention relates to the uses of optical isomers of the novel lipoic acid- related thiazolidinedione and phenyl acetic acid derivatives of the instant invention.
  • optical isomers of ⁇ -lipoic acid R- and S-form, i.e. R- ⁇ -lipoic acid and S- ⁇ -lipoic acid
  • racemate Biewenga et al. "An overview of lipoate chemistry.”
  • Lipoic Acid in Health and Disease. Fruchs J, Packer L, Zimmer G, eds.), Marcel Dekker, Inc.
  • the R- enantiomer mainly has an anti-inflammatory activity, for example, being stronger by a factor of 10 than that of the racemate (Ulrich et al. United States Patent 5,728,735 March 17, 1998), and has been shown to have superior insulin-sensitizing activity and to confer improved cardiac function (Zimmer G et al. J Mol Cell Cardiol. 27:1895-903 (1995)) and ameliorate diabetic peripheral and autonomic neuropathy (Ziegler D, Gries FA. Diabetes. 46 Suppl 2:S62-6 (1997)). In contrast, the S-enantiomer has been shown to be more effective as an anti-nociceptive agent.
  • the anti- nociceptive (analgesic) activity of the S-enantiomer is for example stronger by a factor of 5 to 6 than that of the racemate (Ulrich et al. United States Patent 5,728,735 March 17, 1998). Accordingly, the R- and S-enantiomers of the novel lipoic acid-related thiazolidinedione and phenyl acetic acid derivatives are considered to have superior efficacy in the treatment of specific diseases. For example, a particular stereoisomer, e.g. R-(+)- ⁇ -lipoic stereoisomeric thiazolidinedione derivative is expected to have superior anti-inflammatory activity whereas the corresponding optical isomers are expected to provide greater efficacy in the treatment of other diseases. In addition, the ⁇ -lipoic acid racemate and R and S isomeric forms display anti-inflammatory, anti-nociceptive (analgesic) and cytoprotective properties.
  • lipoic acid The metabolism of lipoic acid has been studied in Pseudomonas (Furr et al., Arch. Biochem. Biophys. 185:576-583 (1978)) and in rats (Spence et al., Arch. Biochem. Biophys. 174:13-19 (1976); Gal et al., Arch. Biochem. Biophys. 89:253-261 (1960); Harrison et al., Arch. Biochem. Biophys. 160:514-522 (1974)). It has been found that in these species lipoic acid is converted by beta oxidation of its pentanoic acid side chain. Regarding the antioxidant activity of lipoic acid, it has been proposed that reduction of lipoic acid to dihydrolipoic acid is an important step in its therapeutic effect.
  • UV-induced formation of free radical particularly activated oxygen radicals.
  • Moisturizers can readily reverse the appearance of dryness regardless of whether it results from low humidity conditions or UN light, and relieve the tautness of the skin caused by UV light and the flaccidity and dryness caused by the aging process. These products either attract moisture from the environment to the skin's surface, or reduce the amount of moisture in the skin that can escape into the environment. These products also add needed moisture to the skin from the formulation itself, and add a layer of emollients on the skin surface to leave it softer and more supple.
  • Sunscreen products are known to protect the skin from some of the harmful effects of UV exposure. These products contain molecules that absorb the harmful wavelengths of ultraviolet light before they can reach the skin. The absorbed light is converted to heat and rapidly dissipated to the skin and environment, which allows these molecules to revert to a lower energy state, and subsequently absorb another photon of light. In this manner, sunscreen agents can absorb numerous photons of ultraviolet light in a relatively short period of time. By absorbing the harmful wavelengths of light, sunscreen products prevent many of the acute and chronic effects caused by ultraviolet light.
  • sunscreen products are not perfect in their mode of action. There is no single sunscreen agent that is capable of absorbing all of the harmful wavelengths striking the skin.
  • Higher Sun Protection Factor (SPF) formulations address this problem by including a combination of sunscreen agents in the formulation.
  • SPPF Sun Protection Factor
  • these products do not provide complete protection, particularly from the longer ultraviolet wavelengths.
  • these longer wavelengths do not readily elicit many of the acute damaging effects commonly attributed to ultraviolet light exposure, recent research indicates that these wavelengths can create free radicals in the skin. These free radicals may be responsible for the premature aging of the skin commonly linked to ultraviolet light exposure.
  • ROS reactive oxygen species
  • These defenses include the presence of enzymes such as superoxide dismutase, catalase, glutathione transferase, glutathione peroxidase and glutathione reductase, as well as antioxidants such as tocopherols, ubiquinone, ubiquinol, ascorbic acid and dehydroascorbic acid.
  • enzymes such as superoxide dismutase, catalase, glutathione transferase, glutathione peroxidase and glutathione reductase
  • antioxidants such as tocopherols, ubiquinone, ubiquinol, ascorbic acid and dehydroascorbic acid.
  • thiobarbituric acid reactive substances present in the skin represent a collection of molecules that are formed from ROS.
  • Prostaglandins, inflammatory interleukins are and other mediators of inflammation that are believed to be produced concomitant to ROS production and the kind of skin damage described above may create conditions that promote the formation of prostaglandins and sunburn cells.
  • mediators of inflammation are formed from arachidonic acid upon oxidation via the lipoxygenase pathway, and by free radical-induced (e.g. superoxide-induced) activation of nuclear factors, such as NF- ⁇ B, AP-1 and NFAT, that promote the expression of inflammatory cytokines.
  • Vitamins such as Vitamin E acetate and succinate
  • Vitamin A palmitate has been shown to create smoother skin and help enhance the process of cellular turnover. This enhancement rids the skin of the outermost dead layer of skin by bringing more youthful appearing skin cells to the surface.
  • Other materials such as hyaluronic acid and pyrrolidone carboxylic acid (PCA), have also been used for their ability to enhance the moisture binding capacity of the skin and therefore lead to smoother, softer skin.
  • compositions that incorporate Vitamins A or E, or their derivatives, in sunscreen compositions are shown in U.S. Pat. Nos. 4,454,112; 5,532,805; and 5,378,461.
  • Vitamin C in combination with Vitamins A, E, B and other agents in a skin protectant composition, is described in U.S. Pat. No. 4,938,960.
  • An antioxidant preparation that is said to protect the skin against harmful ultraviolet radiation is disclosed in U.S. Pat. No. 5,607,921, and contains Vitamin C, in combination with Vitamins A and E, and monosaccharide or amide precursors.
  • Sunscreen compositions containing panthenol and other agents are disclosed in U.S. Pat. Nos.
  • the present invention relates to pharmaceutical compositions or salts and solvates thereof, containing isolipoic acid, R- ⁇ -lipoic acid, S- ⁇ -lipoic or their derivatives, as an active ingredient.
  • the compositions are useful because they inhibit, for example, inflammatory and proliferative processes, and oppose or ameliorate the oxidative stress imposed on organismal physiological processes, including the mediation of cytoprotective effects on cells, resulting in improved cell health and survival.
  • Another aspect of this invention extends to metabolites of ⁇ -lipoic acid, including but not limited to 3-keto-lipoic acid, racemic dihydrolipoic acid, racemic lipoamide, and their optical isomers, R and S optical isomers. Differences exist between the optical isomers of ⁇ -lipoic acid compared to the racemate,
  • the R-enantiomer acts mainly as an anti-inflammatory and the S-enantiomer mainly as an analgesic, the optical isomers of ⁇ -lipoic acid being a number of times stronger (for example by at least a factor of 5) than the racemate of . ⁇ -lipoic acid.
  • the R-enantiomer mainly has an anti-inflammatory activity, for example, being stronger by a factor of 10 than that of the racemate.
  • the R-enantiomer has been shown to have insulin-sensitizing activity and improve diabetes-related organ damage, in particular diabetic neuropathy, hi contrast, the S-enantiomer has been shown to be more effective as an anti-nociceptive agent.
  • the anti-nociceptive (analgesic) activity of the S-enantiomer is for example stronger by a factor of 5 to 6 than that of the racemate.
  • the enantiomers therefore constitute very much more specific and stronger acting active substances than the racemate.
  • one aspect of the present invention provide improved pharmaceutical compositions which have, in particular, analgesic and anti-inflammatory activity.
  • the invention relates to pharmaceutical compositions containing as active ingredient either R- ⁇ -lipoic acid or S- ⁇ - lipoic acid (i.e. the optical isomers of ⁇ -lipoic acid or derivatives thereof) or isolipoic acid or derivatives thereof, or a pharmaceutically acceptable salt of these compounds, their preparation and their use for the preparation of appropriate pharmaceutical and cosmeceutical compositions. These are particularly suitable for combating pain and inflammation.
  • a cytoprotective activity is also obtained.
  • the amounts by weight set out herein relate, in each case, to the purely optical isomers of ⁇ -lipoic acid derivatives where applicable, i.e. not to the salts.
  • the appropriate amounts must correspond in each case to the amounts of the free acid and be increased according to the gram-molecular weight of the salt.
  • This invention comprises the synthesis of novel synthetic lipoic acid derivatives and compositions thereof, and their use cosmetic, nutritional and pharmaceutical uses.
  • the subject invention relates to compositions for oral, intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular or topical application. Oral delivery is the preferred method of administration for most nutritional and pharmaceutical uses.
  • compounds described in this invention are administered orally as are anti-oxidant vitamins (e.g. vitamin C or vitamin E) or vitamin-like substances (e.g. flavonoids such flavones, isoflavones, tocotrienols, and polyphenols).
  • these pharmaceutical compositions have a cytoprotective activity and are suitable for combating pain and inflammation.
  • the synthetic lipoic acid derivatives described in the instant invention are useful for systemic administration for use in the treatment of free radical mediated diseases, including inflammatory, proliferative, neurodegenerative, autoimmune, metabolic and infectious diseases and complications thereof.
  • free radical mediated diseases including inflammatory, proliferative, neurodegenerative, autoimmune, metabolic and infectious diseases and complications thereof.
  • the related complications include diabetic nephropathy, diabetic retinopathy, atherosclerosis (e.g. ischemic heart disease, cerebrovascular disease, peripheral vascular disease), dyslipidemia (e.g.
  • compositions are also useful for conditioning desquamating, and cleansing the skin and for relieving dry skin.
  • These compositions can be in the form of leave-on products or products that are rinsed or wiped from the skin after use.
  • the composition contains certain active ingredients including at least one cyclic polyanionic polyols, and/or at least one zwitterionic surfactant.
  • Topical, intradermal, subcutaneous, intramuscular delivery are preferred methods of administration for most cosmetic uses, including their use in preventing skin aging and wrinkle formation, improving skin turgor and elasticity, improving or eliminating wrinkles, and improving the feel and visual appearance of skin, especially human facial skin.
  • the composition includes an antioxidant lipoic acid derivative in combination with other antioxidant species such as panthenol, grape seed extract, vitamin C, vitamin E, vitamin A or other retinoid, and superoxide dismutase, which exhibit a synergistic effect in protecting the skin from the adverse effects of desiccation, aging, ultraviolet radiation, and the appearance of aging.
  • other antioxidant species such as panthenol, grape seed extract, vitamin C, vitamin E, vitamin A or other retinoid, and superoxide dismutase, which exhibit a synergistic effect in protecting the skin from the adverse effects of desiccation, aging, ultraviolet radiation, and the appearance of aging.
  • R 2 - R- . are selected from the group consisting of: H; an optionally substituted alkyl; a branched alkyl; a cycloalkyl; a bicycloalkyl; a tricycloalkyl; a bicycloalkenyl; a tricycloalkenyl; an alkenyl; an allenyl; a cycloalkenyl; an alkylcycloalkyl; an alkylcycloalkenyl; an alkynyl; an aryl; an arylmethylenyl; an arylethylenyl; a heteroalkyl; a heterocyclic; a heteroaromatic; an alkylheterocyclic; an alkylheteroaryl; an alcohol; an ether OR 5 ; a mono-, di-, or unsubsituted amine (NR 6 R 7 );
  • compositions of the present invention are useful for topical application to human skin and for systemic (oral) use in mammals, including humans. Details of preparing these compositions are provided in the following appendices.
  • the preferred method of delivery is topical application to the skin.
  • These compositions provide improved skin feel, and can be in the form of leave-on products or products that are rinsed or wiped from the skin after use.
  • These compositions are also useful for conditioning the skin, for desquamating the skin, for cleansing and clarifying the skin, for reducing skin pore size, and also for relieving dry skin.
  • compositions which give the skin a smooth and elegant skin feel, which are useful for treating dry skin, and which are useful for providing a desquamation benefit.
  • cleansing products have these attributes.
  • composition which are also useful for delivering a wide variety of active ingredients to the skin, either directly to the skin or during the cleansing process.
  • skin care compositions containing a combination of amphoteric surfactants, anionic surfactants, and cationic surfactants are useful for providing these skin care benefits. It is therefore an object of the present invention to provide skin care compositions for topical application to the skin. It is another object of the present invention to provide skin care compositions having improved skin conditioning properties, and which are also mild and nonirritat-ng to the skin.
  • physical insult e.g. desiccation, sunlight, UV radiation in sunlight
  • chemical insult e.g. dehydration from excessive washing, caustic solvents.
  • This invention comprises the synthesis of novel synthetic lipoic acid derivatives and compositions thereof, and their use cosmetic, nutritional and pharmaceutical uses.
  • the subject invention relates to compositions for oral, intravenous, intradermal, subcutaneous, intramuscular or topical application. Oral delivery is the preferred method of administration for most nutritional and pharmaceutical uses.
  • compounds described in this invention are administered orally as are anti-oxidant vitamins (e.g. vitamin C or vitamin E) or vitamin-like substances (e.g. flavonoids such flavones, isoflavones and polyphenols).
  • Topical, intradermal, subcutaneous, intramuscular delivery are preferred methods of administration for most cosmetic uses, including their use in preventing skin aging and wrinkle formation, improving skin turgor and elasticity, improving or eliminating wrinkles, and improving the feel and visual appearance of skin, especially human facial skin.
  • these compositions are also useful for conditioning desquamating, and cleansing the skin and for relieving dry skin.
  • These compositions can be in the form of leave-on products or products that are rinsed or wiped from the skin after use.
  • the composition contains certain active ingredients including at least one cyclic polyanionic polyols, and/or at least one zwitterionic surfactant.
  • these pharmaceutical compositions have a cytoprotective activity and are suitable for combating pain and inflammation.
  • the natural and synthetic lipoic acid derivatives and their metabolites as described in the instant invention are useful for systemic administration for use in preventing skin aging and in the treatment of free radical mediated diseases, including inflammatory, proliferative, neurodegenerative, metabolic and infectious diseases and the complications.
  • free radical mediated diseases including inflammatory, proliferative, neurodegenerative, metabolic and infectious diseases and the complications.
  • the related complications include diabetic nephropathy, diabetic retinopathy, atherosclerosis, ischemic heart disease, dyslipidemia, atherogenesis, thrombosis, and endothelium-related and inflammatory dysfunctions in diabetes (see Tables I through VII) .
  • Salt formers that may be considered for R- ⁇ -lipoic acid and S- ⁇ -lipoic acid are, for example, conventional bases or cations which are physiologically acceptable in the salt form.
  • Examples include: alkali metals or alkaline earth metals, ammonium hydroxide, basic amino acids such as arginine and lysine, amines having the formula NR1, R2, R3 in which the radicals RI, R2, and R3 are the same or different and represent hydrogen, CI, -C4, -alkyl or CI, -C4, -oxyalkyl, such as mono- and diethanolamine, l-amino-2-propanol, 3-amino-lpropanol; alkylene diamine with an alkylene chain consisting of 2 to 6 carbon atoms, such as ethylenediamine or hexamethylene tetramine, saturated cyclic amino compounds having 4-6 ring carbon atoms such as piperidine, piperazine, pyrrolidine. morph
  • the therapeutic compound is optionally administered topically by the use of a transdermal therapeutic system (see, Barry, Dermatological Formulations, (1983) p. 181 and literature cited therein). While such topical delivery systems have been designed largely for transdermal administration of low molecular weight drugs, by definition they are capable of percutaneous delivery. They can be readily adapted to administration of the therapeutic compounds of the invention by appropriate selection of the rate-controlling microporous membrane.
  • the therapeutic compound is formulated into solutions, suspensions, and ointments appropriate for use in the eye.
  • concentrations are usually as discussed above for topico-local preparations.
  • the therapeutic compound is alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound.
  • a nonaqueous (e.g., fluorocarbon propellent) suspension could be used.
  • Sonic nebulizers are preferred because they minimize exposing the therapeutic compound to shear, which can result in degradation of the compound.
  • an aqueous aerosol is made by formulating an aqueous solution or suspension of the therapeutic compound together with conventional pharmaceutically acceptable carriers and stabilizers.
  • the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
  • Aerosols generally are prepared from isotonic solutions.
  • either solid or fluid unit dosage forms can be prepared.
  • the compound of interest is mixed into formulations with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methylcellulose, and functionally similar materials as pharmaceutical diluents or carriers.
  • Capsules are prepared by mixing the compound of interest with an inert pharmaceutical diluent and filling the mixture into a hard gelatin capsule of appropriate size.
  • Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound of interest with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
  • Fluid unit dosage forms for oral administration such as syrups, elixirs and suspensions can be prepared.
  • the water soluble forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavoring agents and preservatives to form a syrup.
  • An elixir is prepared by using a hydroalcoholic (e.g., ethanol) vehicle with suitable sweeteners such as sugar and saccharin, together with an aromatic flavoring agent.
  • Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • Slow or extended-release delivery systems including any of a number of biopolymers (biological-based systems), systems employing liposomes, and polymeric delivery systems, can be utilized with the compositions described herein to provide a continuous or long term source of therapeutic compound.
  • Such slow release systems are applicable to formulations for topical, ophthalmic, oral, and parenteral use. _ _ _ _ .
  • the single dose of active ingredient of may for example be: a) in the oral medicinal form between 100 mg-3 g, preferably 200 mg-1 g. b) in parenteral medicinal forms (for example intravenous, intramuscular) between 100 mg- 12 g, preferably 200 mg-6 g. c) in medicinal forms for inhalation (solutions or aerosols) between 100 mg-2 g, preferably
  • the doses according to a) to d) may for example be administered 1 to 6 times, preferably 1 to 3 times daily or, however, as a permanent infusion, for example with the aid of an infusoniate, i.e., with an infusion apparatus for accurate hourly dosage of an active substance in solution.
  • the daily dose of a lipoic acid derivative in humans should for example be between 70-80 mg per kg weight; the single dose for example 16-20 mg per kg body weight, this dose appropriately being given 1-4 times daily: the pharmaceutical compositions therefore preferably contain 250 mg-1.5 g of the lipoic acid derivative in a pharmaceutical formulation, a dose of this type preferably being given 1-3 times each day.
  • the recommended treatment is, for example, 3 times daily, 1 to 4 tablets with a content of
  • the minimum daily dose is for example 300 mg; the maximum daily dose, given orally, should not exceed 12 g.
  • R- or S- ⁇ -lipoic acid derivative Should these be used in the form of their salts, the quoted dosages/dosage ranges should be increased in accordance with the higher molecular weight of the salts.
  • the formulations/products of the invention may preferably also contain additional vitamins, in particular vitamin B 1 and/or vitamin E.
  • appropriate pharmaceutical compositions should contain such an amount of the (RS)-enantiomer, R- or S- ⁇ - lipoic acid or a lipoic acid derivative, this should be administered in such an amount, that single or repeated application achieves in the body a level of activity between 3.5 and 200 mg/kg, preferably 7 and 100 mg, in particular between 35 and 70 mg/kg body weight.
  • the general dose range of S- ⁇ -lipoic acid that may be considered is, for example: 1-100 mg/kg orally.
  • the general dose range of R- ⁇ -lipoic acid that may be considered is, for example: 1-100 mg/T g orally.
  • S- ⁇ -lipoic acid or respective derivative Apart from its anti-nociceptive (analgesic) main activity, S- ⁇ -lipoic acid or respective derivative also possesses an anti-inflammatory and cytoprotective activity, however to a lesser extent. In addition to the main anti-inflammatory and anti-arthritic activity, R- ⁇ -lipoic acid also has anti-nociceptive and cytoprotective activity, albeit to a lesser extent.
  • optical isomers of ⁇ -lipoic acid or isolipoic acid or derivative thereof display a good analgesic, anti-inflammatory, antiproliferative, neuroprotective, immunosuppressive, anti- artherosclerotic, anti-atherogenetic, anti-stenotic, anti-vasuloocclusive and cytoprotective activity in, for example investigative models of these diseases. Indications that may for example be considered are described in Tables I through VII.
  • the daily doses of the dosage forms of the invention for analgesic or cytoprotective or anti-inflammatory activity are, for example, 1 to 1000 mg, preferably 15 to 500 mg and in particular 50 to 200 mg of R- ⁇ -lipoic acid or S- ⁇ -lipoic acid or isolipoic acid derivative.
  • the optical isomers of ⁇ -lipoic acid (R- or S-form in each case) are given in a daily dose of 10 to 1000 mg, for example of 25 to 400 mg or 10 to 200 mg.
  • the maximum daily dose for the cytoprotective activity and for the treatment of pain and inflammation should not exceed 1000 mg.
  • the daily doses may be given in the form of a single administration of the total amount in 1 to 6 partial doses per day, preferably in 1-3 times divided doses daily.
  • compositions are preferably administered orally, but may also be administered parenterally (intravenously, intraarticularly, transpulmonary, intramuscularly, subcutaneously, intradermally), or delivered or applied topically in the form of a gel, lotion, cream, solution, suspension, ointment or other suitable delivery vehicle, directly to the skin, intraorally, sublingually, as an inhalation, or per rectum, or per vagina directly applied or as a suppository.
  • compositions containing compounds described in this invention as active ingredient may for example be formulated in the form of tablets, capsules, pills or coated tablets, granulates, pellets, plasters, solutions or emulsions, the active ingredient in each case optionally being combined with appropriate auxiliary and carrier substances.
  • these contain for example 0.01 to 20% by weight, preferably 0.05 to 5% by weight of the enantiomer, or one of the optical isomers of ⁇ -lipoic acid or iso-lipoic acid (in each case either the isoform or R- form or S-form or derivative thereof), or R-form-enriched, or S-form-enriched mixtures of the isomers or derivative thereof.
  • the dosage unit of the pharmaceutical composition with or one of the optical isomers of ⁇ - lipoic acid or iso-lipoic acid may, for example, contain: a) in the case of oral and intravenous medicinal forms: 10 to 2000 mg, preferably 20 to 500 mg, in particular 50 to 200 mg of the compound.
  • the doses may for example be given 1 to 6 times, preferably 1 to 4 times, in particular 1 to 3 times daily. In each case, however, a total dosage of 1000 mg per day should not usually be exceeded for the cytoprotective activity and for the treatment of pain and inflammation.
  • b) in the case of medicinal forms for application to the skin and mucous membranes for example as solutions, lotions, emulsions, ointments, plasters and the like: 0.01 to 20% by weight, preferably 0.05 to 5% by weight of the compound.
  • These doses may for example be administered 1 to 6 times, preferably 1 to 4 times, in particular 1 to 3 times daily.
  • These doses may, for example, be administered 1 to 6 times, preferably 1 to 4 times, in particular 1 to 3 times daily.
  • the compounds are preferably used in the form of a salt. It is of course also possible to prepare pharmaceutical formulations which contain 2 to, for example, 6 times the above mentioned dosage units.
  • the tablets or capsules contain 20 to 500 mg, pellets, powders or granulates 20 to 400 mg, suppositories 20 to 300 mg of a compound of the instant invention.
  • compositions/Formulations for Topical Administration always relate to the free optical isomers of ⁇ -lipoic acid, lipoic acid, and isolipoic acid derivatives as described in this invention. Should the optical isomers of these compounds be used in the form of a salt, the dosages/dosage ranges should be correspondingly increased due to the higher molecular weight.
  • compositions of the present invention are useful for application to human skin. These compositions are useful for conditioning the skin, for desquamating the skin, for treating dry skin, for delivering active ingredients to the skin, and in the cleansing embodiments, for cleansing the skin without over-drying or irritating the skin.
  • amphoteric surfactant of these compositions can potentially complex with both the anionic and cationic surfactant components. Additionally, the anionic surfactant can potentially complex with the cationic surfactant component. These multiple complexes tend to be viscous and lubricious leading to a soft or smooth, elegant skin feel. These complexes are also believed to be highly stable relative to the individual surfactant components.
  • complexes are useful for aiding in the delivery to the skin of any active ingredients which can be present in the compositions.
  • these complexes tend to deposit out from the composition, thereby helping to carry any active ingredients to the skin's surface, while leaving a soft, smooth skin feel.
  • the postulated complexes can contain various combinations of amphoteric, anionic, and cationic surfactants, these complexes are also effective for cleansing the skin and for promoting the desquamation process. Because the charges on the individual surfactants are complexed, the surfactants are tendered less harsh and irritating to the skin versus the free surfactants.
  • compositions of the present invention can be formulated into a wide variety of product types including, but not limited to creams, lotions, mousses, sprays, "rinse-off cleansers, "waterless” cleansers, bars, gels, and the like.
  • the term "rinse”, as used herein, means that the composition is in a form that can be used in a cleansing process whereby the composition is ultimately rinsed or washed from the skin with water to complete the cleansing process.
  • water-less as used herein, means that the composition is in the form that can be used in a cleansing process without water whereby the composition is typically removed by wiping with a device such as a cotton ball, a cotton pad, a tissue, a towel, and the like.
  • compositions and components thereof so described are of sufficiently high purity and are suitable for use in contact with human skin and tissues without undue toxicity, irritation, incompatibility, instability, allergic response, and the like.
  • salts any of the commonly- used salts that are suitable for use in contact with human skin and tissues without undue toxicity, irritation, incompatibility instability, allergic response, and the like.
  • Amphoteric surfactant any of the commonly- used salts that are suitable for use in contact with human skin and tissues without undue toxicity, irritation, incompatibility instability, allergic response, and the like.
  • composition of the present invention comprise from about 0.1% to about 20%, more preferably from about 0.2% to about 10%, and most preferably from about 0.5% to about 5% of an amphoteric surfactant.
  • amphoteric surfactant as used herein, is also intended to encompass zwitterionic surfactants, which are well known to formulators skilled in the art as a subset of amphoteric surfactants.
  • amphoteric surfactants can be used in the compositions of the present invention. Particularly useful are those which are broadly described as derivatives of aliphatic secondary and tertiary amines, preferably wherein the nitrogen is in a cationic state, in which the aliphatic radicals can be straight or branched chain and wherein one of the radical contains an ionizable water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • an ionizable water solubilizing group e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • amphoteric surfactant useful in the compositions of the present invention are disclosed in McCutcheon's, Detergents and Emulsifiers, North American edition (1986), published by allured Publishing Corporation; and McCutcheon's, Functional Materials, North American Edition (1992).
  • Preferred amphoteric or zwitterionic surfactants are the betaines, sultaines, and hydroxysultaines.
  • betaines include the higher alkyl betaines, such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine (available as Lonzaine 16SP from Lonza Corp.), lauryl bis-(2-hydroxyethyl) carboxymethyl betaine, stearyl bis-(2- hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis- (2-hydroxypropyl)alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, stearyl betaine, lauryl dimethyl sulf
  • amphoteric surfactants produced according to the teaching of U.S. Patent 5,607,980 March 4, 1997 and U.S. Patent 5,821,237 October 13, 1998.
  • Preferred amphoteric surfactants of the present invention include cetyl dimethyl betaine, cocoamidopropyl betaine, stearyl dimethyl betaine, and cocoamidopropyl hydroxy sultaine. Still more preferred are cetyl dimethyl betaine, stearyl dimethyl betaine, and cocamidopropyl betaine. Most preferred is cetyl dimethyl betaine.
  • amphoteric surfactants examples include alkyliminoacetates, and iminodialkanoates and aminoalkanoates according to the teaching of U.S. Patent 5,821,237 October 13, 1998.
  • suitable amphoteric surfactants include sodium 3-dodecyl- aminopropionate, sodium 3-dodecylaminopropane sulfonate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Pat. No. 2,658,072; N-higher alkyl aspartic acids such as those produced according to the teaching of U.S. Pat. No.
  • amphoterics include phosphates, such as coamidopropyl PG-dimonium chloride phosphate (commercial available as Monaquat PTC, from Mona Corp.).
  • Anionic surfactant such as coamidopropyl PG-dimonium chloride phosphate (commercial available as Monaquat PTC, from Mona Corp.).
  • compositions of the present invention comprise from about 0.1% to about 20%, more preferably from about 0.2% to about 10%, and most preferably from about 0.5% to about 5% of an anionic surfactant.
  • anionic surfactants useful in the compositions of the present invention are disclosed in McCutcheon's, Detergents and Emulsifiers, North American edition (1986), published by allured Publishing Corporation; McCutcheon's, Functional Materials, North American Edition (1992); and U.S. Pat. No. 3,929,678, to Laughlin et al., issued Dec. 30, 1975.
  • anionic surfactants include the alkoyl isethionates, and the alkyl ether sulfates according to the teaching of U.S. Patent 5,607,980 March 4, 1997 and U.S. Patent 5,821,237 October 13, 1998.
  • Nonlimiting examples of these isethionates include those alkoy isethonates selected from the group consisting of ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, and mixtures thereof, according to the teaching of U.S. Patent 5,607,980 March 4, 1997 and U.S. Patent 5,821,237 October 13, 1998.
  • anionic synthetic surfactants include the class designated as succinamates, olefin sulfonates having about 12 to about 24 carbon atoms, and b-alkyloxy alkane sulfonates. Examples of these materials are sodium lauryl sulfate and ammonium lauryl sulfate.
  • Other anionic materials include the sarcosmates nonlimiting examples of which include sodium lauroyl sarcosinate, sodium cocyl sarcosinate, and ammonium lauroyl carcosinate.
  • Other anionic materials useful herein are soaps (i.e.
  • alkali metal salts e.g., sodium or potassium salts
  • fatty acids typically having from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms.
  • the fatty acids used in making the soaps can be obtained from natural sources such as, for instance, natural animal-derived or plant-derived oil, or the semi-synthetic oil, glycerides, or extracts (e.g., aloe extract, perilla extract, perilla oil, primrose oil, palm oil, coconut oil, soybean oil, caster oil, tallow, lard, avocado oil, linseed oil, almond oil, Chinese wax, perilla oil, olive oil, cacao butter, kapok oil, cajeput oil, carnauba wax, liver oil, candelilla wax, beef tallow, beef foot oil, beef bone fat, hydro genated beef tallow, persic oil, whale oil, hydrogenated oil, wheat germ oil, sesame oil, rice germ oil, rice bran oil, sugarcone wax,
  • anionic materials include phosphates such as monoalkyl, dialkyl, and trialkylphosphate salts.
  • Other anionic materials include alkanoyl sarcosinates corresponding to the formula RCON(CH3)CH2 CH2 C02 M wherein R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and trialkanolamine (e.g., triethanolamine), a preferred example of which is sodium lauroyl sarcosinate.
  • Nonlimiting examples of preferred anionic surfactants useful herein include those selected from the group consisting of sodium lauryl sulfate, ammonium lauryl sulfate, ammonium cetyl sulfate, sodium cetyl surface, sodium stearyl sulfate, ammonium cocoyl isethionate, sodium lauroyl isethionate, sodium lauroyl sarcosinate, and mixtures thereof.
  • Especially preferred for use herein is sodium lauryl sulfate.
  • Cationic surfactant The compositions of the present invention comprise from about 0.1% to about 15%, more preferably from about 0.2% to about 10%, and most preferably from about 0.5% to about 5% of a cationic surfactant.
  • Nonlimiting examples of cationic surfactants useful in the compositions of the present invention are disclosed in McCutcheon's, Detergents and Emulsifiers, North American edition (1986), published by allured Publishing Corporation; and McCutcheon's, Functional Materials, North American Edition (1992).
  • Nonlimiting examples of cationic surfactants useful herein include cationic ammonium salts according to the teaching of U.S. Patent 5,607,980 March 4, 1997 and U.S. Patent 5,821,237 October 13, 1998.
  • cationic surfactants include amino-amides according to the teaching of U.S. Patent 5,607,980 March 4, 1997 and U.S. Patent 5,821,237 October 13, 1998.
  • Nonlimiting examples of these cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof.
  • Nonlimiting examples of quaternary ammonium salt cationic surfactants include those selected from the group consisting of cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium bromide, lau
  • Additional quaternary ammonium salts include those wherein the C 12 to C22 alkyl carbon chain is derived from a tallow fatty acid or from a coconut fatty acid.
  • tallow refers to an alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixture of alkyl chains in the C16 to C18 range.
  • coconut refers to an alkyl group derived from a coconut fatty acid, which generally have mixtures of alkyl chains in the C12 to C14 range.
  • Examples of quaternary ammonium salts derived from these tallow and coconut sources include ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, di(hydrogenated tallow) dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammoniums nitrate, di(coconutalkyl)dimethyl ammonium chloride, di(coconutalkyl)dimethyl ammonium bromide tallow ammonium chloride, coconut ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosy
  • Preferred cationic surfactants useful herein include those selected from the group consisting of dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, and mixtures thereof.
  • compositions of the present invention comprise from about 45% to about 99.7%, more preferably from about 60% to about 95%, and most preferably from about 70% to about 90% of water.
  • the exact level of water will depend upon the form of the product and the desired moisture content. Additional components
  • compositions of the present invention can comprise a wide range of additional components.
  • CTFA Cosmetic Ingredient Handbook Second Edition, 1992, describes a wide variety of cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention.
  • Nonlimiting examples of functional classes of ingredients are described at page 537 of this reference.
  • Examples of these functional classes include: absorbents, abrasives, anti-acne agents, anticaking agents, antifoaming agents, antimicrobial agents, antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers, fragrance components, humectants, opacifying agents, pH adjusters, plasticers, preservatives, propellants, reducing agents, skin bleaching agents, skin-conditioning agents (emollient, humectants, miscellaneous, and occlusive), skin protectants, solvents, foam boosters, hydrotropes, solubilizing agents, suspending agents (nonsurfactant), sunscreen agents, ultraviolet light absorbers, and viscosity increasing agents (aqueous and nonaqueous).
  • absorbents abrasives, anti-acne agents, an
  • Nonlimiting examples of these additional components cited in the CTFA Cosmetic Ingredient Handbook, as well as other materials useful herein, include the following: vitamins and derivatives thereof [e.g., vitamin C, Vitamin A (i.e. retinoic acid), retinol, esters of retinoic acid, esters of retinol, retinoids, pathenol, pathenol esters, tocopherol, tocopherol esters, phytic acid, phytic acid esters, lycopene, flavones, flavonones, isoflavones, flavonols and other flavonoids]; oil or sebum control agents such as clays silicones and drug actives; sunscreening agents; other silicone material such as dimethiconol, dimethicone copolyol, and amodimethicone, and the like; antioxidants; anti-microbial agents; preservatives; emulsifiers; polyethylene glycols and polypropylene glycols; polymers for aid
  • anti-acne medicaments e.g., resorcinol, sulfur, salicylic acid, erythromycin, zinc, and the like
  • skin bleaching (or lightening) agents including but not limited
  • SC92 which has the CTFA designation polyquaternium 32 (and) mineral oil, and Salcare.RTM. SC95 which has the CTFA designation polyquaternium 37 (and) mineral oil (and) PPG-1 trideceth-6, and the nonionic Seppi-Gel polyacrylamides available from Seppic Corp.]; proteins and peptides; enzymes; ceramides; aesthetic components such as fragrances, pigments, colorings, essential oils, skin senates, astringents, skin soothing agents, skin healing agents and the like, [nonlimiting examples of these aesthetic components include clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, bisabolol, dipotassium glycyrrhizinate and the like]; and skin conditioning agents such as urea and glycerol, and also the propoxylated glycerols described in U.S. Pat. No. 4,976,953, or
  • compositions of the present invention comprise a safe and effective amount of one or more active ingredients of pharmaceutically-acceptable salts thereof.
  • safe and effective amount means an amount of an active ingredient high enough to modify the condition to be treated or to deliver the desired skin benefit, but low enough to avoid serious side effects, at a reasonable benefit to risk ratio within the scope of sound medical judgement. What is a safe and effective amount of the active ingredient will vary with the specific active, the ability of the active to penetrate through the skin, the age, health condition, and skin condition of the user, and other like factors.
  • the active ingredients of the present invention comprise from about 0.001% to about 20%, preferably from a bout 0.01% to about 15%, and more preferably from about 0.025% to about 10%) by weight of the composition.
  • the active ingredients useful herein can be categorized by their therapeutic benefit or their postulated mode of action. However, it is to be understood that the active ingredients useful herein can in some instances provide more than one therapeutic benefit or operate via more than one mode . » --. of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active ingredient to that particular application or applications listed. Also, pharmaceutically-acceptable salts of these active ingredients are useful herein. The following active ingredients are useful in the compositions of the present invention.
  • Anti-Acne Actives examples include the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid, and resorcinol; retinoids such as retinoic acid and its derivatives (e.g., cis and trans); sulfur- containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, a preferred example of which is N-acetyl-L-cystein; lipoic acid; antibiotics and antimicrobials such as benzoyl peroxide, octopirox, tetracycline, 2,4,4 '-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide.
  • keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid, and
  • azelaic acid and its derivatives phenoxyethanol, phenoxypropanol, phenoxisopropanol, ethyl acetate, clindamycin and meclocycline; sebostats such as flavonoids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate, and cholate.
  • antiwrinkle and anti-skin atrophy actives include retinoic acid and its derivatives (e.g., cis and trans); retinol, retinyl esters, salicylic acid and derivatives thereof; sulfur- containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, e.g. N-acetyl-L-cysteine; thiols, e.g., ethane thiol; alpha-hydroxy acids, e.g. glycolic acid, and lactic acid; phytic acid, lysophosphatidic acid, azelaic acid, and skin peel agents (e.g., phenol).
  • retinoic acid and its derivatives e.g., cis and trans
  • retinol retinyl esters
  • salicylic acid and derivatives thereof sulfur- containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives,
  • NSAIDS include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are fully described in U.S. Pat. No. 4,985,459 to Sunshine et al., issued Jan. 15, 1991.
  • NSAIDS examples include acetyl salicylic acid, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, piiprofen, carprofen, oxaprozin, pranoprofen, microprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid.
  • steroidal anti-inflammatory drugs including hydrocortisone and the like.
  • Topical Anesthetics examples include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexyclaine, procaine, cocaine, keta ine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
  • Artificial Tanning Agents and Accelerators include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexyclaine, procaine, cocaine, keta ine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
  • artificial tanning agents and accelerators include dihydroxyacetone, tyrosine, tyrosine esters such as ethyl tyrosinate, and phospho-DOPA. Antimicrobial and Antifungal Actives.
  • antimicrobial and antifungal actives examples include .beta.-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, phenoxyethanol, phenoxy propanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methena ine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole, tetracycline hydroch
  • plant-derived compounds with estrogen-like activity are also useful herein.
  • Particular examples of these plant-derived compounds with estrogen-like compounds include isoflavones, especially soy-derived isoflavones, such as genistein and daidzein. Sunscreen Actives.
  • sunscreening actives are also useful herein .are sunscreening actives.
  • a wide variety of sunscreening agents are described in U.S. Pat. No. 5,087,445, to Haffey et al., issued Feb. 11, 1992; U.S. Pat. No. 5,073,372, to Turner et al., issued Dec. 17, 1991; U.S. Pat. No. 5,073,371, to Turner et al. issued Dec. 17, 1991; and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetic Science and Technology.
  • Nonlimiting examples of sunscreens which are useful in the compositions of the present invention are those selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl-N,N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole-5- sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-t- butyldibenzoylmethane, 4-isopropy dibenzoylmethane, 3-benzylidene camphor, 3-(4- methylbenzylidene) camphor, titanium dioxide, zinc oxide, silica, iron oxide, and mixtures thereof.
  • sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultraviolet radiation absorption spectra.
  • One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.
  • sunscreens include those selected from the group consisting of 4-N,N- (2-ethylhexyl)methylaminobenzoic acid ester of 2,4-dihydroxy-benzophenone, 4-N,N-(2- ethylhexyl)-methylaminobenzoic acid ester with 4-hydroxydi-benzoylmethane, 4-N,N-(2- ethylhexyl)-methylaminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)- benzophenone, 4- N,N-(2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)- dibenzoylmethane, and mixtures thereof.
  • the sunscreens can comprise from about 0.5% to about 20% of the compositions useful herein. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF). SPF is a commonly used measure of photoprotection of a sunscreen against erythema. See Federal Register, Vol. 43, No. 166, pp. 38206-38269, Aug. 25, 1978.
  • actives useful herein include those selected from the group consisting of salicylic acid, 3-hydroxy benzoic acid, glycolic acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid,2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetaminophen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'- trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichloroc.arbailide, octopirox, lido
  • actives useful herein include those selected from the group consisting of salicylic acid, benozyl peroxide, acetyl salicylic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cystein, lipoic acid, azelaic acid, tetracycline, ibuprofen, naproxen acetominophen, hydrocortisone, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, 2-phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
  • actives useful herein include those selected from the group consisting of salicylic acid, benzoyl peroxide, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl L-cysteine, azelaic acid, lipoic acid, resorcinol, lactic acid, glycolic acid, ibuprofen, naproxen, hydrocortisone, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro- 2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, 2-ethylhexyl p-methoxycinnamic acid, oxybenzone, 2-phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
  • compositions of the present invention can also comprise one or more humectants or moisturizers.
  • humectants or moisturizers A variety of these materials can be employed and each can be present at a level of from about 0.1% to about 20%, more preferably from about 0.5% to about 15%, and most preferably from about 1% to about 10%.
  • Nonlimiting examples of humectants include materials selected from the group consisting of guanidine; glycolic acid and glycolate salts (e.g., ammonium and quaternary alkyl ammonium); lactic acid and lactate salts (e.g., ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g., aloe vera gel); polyhydroxy alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; polyethylene glycols; sugars and starches; sugar and starch derivatives (e.g., alkoxylated glucose); hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; and mixtures thereof.
  • glycolic acid and glycolate salts e.g., ammonium and quaternary alkyl ammonium
  • lactic acid and lactate salts
  • compositions of the present invention can comprise from about 0.1% to about 20%, more preferably from about 0.25% to about 15%, and most preferably from about 0.5% to about 10%, based on the weight of the total composition, of insoluble particles which are useful for enhancing the cleansing effect, when the compositions of the present invention are in the form of a cleansing composition.
  • insoluble means that the particles are essentially insoluble in the compositions of the present invention.
  • the insoluble particles should have a solubility less than about 1 gram per 100 grams of composition at 25 degree C, preferably less than about 0.5 grams per 100 grams of composition at 25 degree C, and more preferably less than about 0.1 grams per 100 grams of composition at 25 degree C.
  • micronized particles are of a size that is below the tactile threshold and are essentially nonabrasive to the skin.
  • the conventional size particles are tactilely perceptible and are added for the scrubbing and abrasive effect which they provide.
  • the micronized particles have a mean particle size diameter and particle size distribution such that they are below the tactile perception threshold of most users, and yet are not so small as to be ineffective for aiding in oil, dirt, and debris (e.g., make-up) removal.
  • particles having a mean particle size diameter greater than about 75 microns are tactilely perceived during the cleansing process and it is important to minimize the amount of these larger particles if it is desired that the particles not be felt by the user.
  • particles having a means particle size diameter of less than about 1 to about 5 microns are generally less effective for providing a cleansing benefit.
  • the micronized cleansing particles should be of a size that is on the order of the thickness of the dirt, oil, or debris layer to be cleaned away. This layer is believed to be on the order of a few microns in thickness in most instance.
  • the micronized particles should have a mean particle size diameter from about 1 to about 75 microns, more preferably from about 15 to about 60 microns, and most preferably from about 20 to about 50 microns, so as to provide effective cleansing without being tactilely perceptible. Particles having a wide range of shapes, surface characteristics, and hardness characteristics can be utilized herein provided the particle size requirements are met. Micronized particles of the present invention can be derived from a wide variety of materials including those derived from inorganic, organic, natural, and synthetic sources.
  • Nonlimiting examples of these materials include those selected from the group consisting of almond meal, alumina, aluminum oxide, aluminum silicate, apricot seed powder, attapulgite, barley flour, bismuth oxychloride, boron nitride, calcium carbonate, calcium phosphate, calcium pyrophosphate, calcium sulfate, cellulose, chalk, chitin, clay, corn cob meal, com cob powder, corn flour, corn meal, corn starch, diatomaceous earth, dicalcium phosphate, dicalcium phosphate dihydrate, fullers earth, hydrated silica, hydroxyapatite, iron oxide, jojoba seed powder, kaolin, loofah, magnesium trisilicate, mica, microcrystalline cellulose, montmorillonite, oat bran, oat flour, oatmeal, peach pit powder, pecan shell powder, polybutylene, polyethylene, polyisobutylene, polymethylstyrene, polypropylene, polystyrene
  • polytetrafluoroethylene polyhalogenated olefins
  • pumice rice bran pumice rice bran
  • rye flour cericite
  • silica silk
  • sodium bicarbonate sodium silicoaluminate
  • soy flour synthetic hectorite talc
  • tin oxide titanium disoide
  • tricalcium phosphate walnut shell powder, wheat bran, wheat flour, wheat starch, zirconium silicate, and mixtures thereof.
  • micronized particles made from mixed polymers (e.g., copolymers terpolymers, etc.), such as polyethlene/polypropylene copolymer, polyethylene/propylene/isobutylene copolymer, polyethlene/styrene copolymer, and the like.
  • the polymeric and mixed polymeric particles are treated via an oxidation process to destroy impurities and the like.
  • the polymeric and mixed polymeric particles can also optionally be crosslinked with a variety of common crosslinking agents, nonlimiting examples of which include butadiene, divinyl benzene, methylenebisacrylamide, allyl ethers of sucrose, allyl ethers of pentaerythritol, and mixtures thereof.
  • Other examples of useful micronized particles include waxes and resins such as paraffins, carnuba wax, ozekerite wax, candellila wax, urea-formaldehyde resins, and the like. When such waxes and resins are used herein it is important that these materials are solids at ambient and skin temperatures.
  • water-insoluble, micronized particulate materials useful herein are the synthetic polymeric particles selected from the group consisting of polybutylene, polyethylene, polyisobutylene, polymethylstyrene, polypropylene, polystyrene, polyurethane, nylon, Teflon, and mixtures thereof. Most preferred are polyethylene and polypropylene micronized particles, with the oxidized versions of these materials being especially preferred. Examples of commercially available particles useful herein include the ACumist.TM. micronized polyethylene waxes available from Allied Signal (Morristown, NJ.) available as the A, B, C, and D series in a variety of average particle sizes ranging from 5 microns to 60 microns.
  • ACumist.TM A-25, A-30, and A-45 oxidized polyethylene particles having a mean particle size of 25, 30, and 45 microns, respectively.
  • Examples of commercially available polypropylene particles include the Porpyltex series available from Micro Powders (Dartek).
  • the conventional size insoluble particles are well-known to formulation chemists in the art. These particles typically have larger particle sizes than the micronized particles described herein. These particles generally have an average size diameter that is about 75 microns or greater, which is above the tactile threshold described above. These conventional size particles typically have average particles sizes ranging up to about 400 microns and larger. These particles can be made from the same materials as for the micronized particles just described.
  • the preferred conventional size particulate materials useful herein are the synthetic polymeric particles selected from the group consisting of polybutylene, polyethylene, polyisobutylene, polymethylstyrene, polyethylene and polypropylene micronized particles, with the oxidized versions of these materials being especially preferred.
  • An example of a commercially available conventional size particle useful herein is ACuscrub.TM.51, available from Allied Signal (Morristown, N.J.) having a mean particle size of about 125 microns. Emulsifiers.
  • compositions herein can comprise various emulsifiers. These emulsifiers are useful for emulsifying the various carrier components of the compositions herein. Suitable emulsifiers can include any of a wide variety of nonionic, cationic, anionic, and zwitterionic emulsifiers disclosed in the prior patents and other references. See McCutcheon's, Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation; U.S. Pat. No. 5,011,681 to Ciotti et al., issued Apr. 30, 1991; U.S. Pat. No. 4,421,769 to Dixon et al., issued Dec. 20, 1983; and U.S. Pat. No. 3,755,560 to Dickert et al., issued Aug. 28, 1973.
  • Suitable emulsifier types include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps and mixtures thereof.
  • Suitable emulsifiers can include, but are not limited to, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG- 100 stearate, and mixtures thereof.
  • the emulsifiers can be used individually or as a mixture of two or more and can comprise from about 0.1% to about 10%, more preferably from about 0.15% to about 7%, and most preferably from about 0.2% to about 5% of the compositions of the present invention. Oils
  • compositions of the present invention can comprise from about 0.25% to about 40%, preferably from about 0.5% to about 25%, and more preferably from about 0.75% to about 15% of an oil selected from the group consisting of mineral oil, petrolatum, C7-C40 branched chain hydrocarbons, C1-C30 alcohol esters of C1-C30 carboxylic acids, C1-C30 alcohol esters of C2-C30 dicarboxylic acids, monoglycerides of C1-C30 carboxylic acids, diglycerides of C1-C30 carboxylic acids, triglycerides of C1-C30 carboxylic acids, ethylene glucol monoesters of C1-C30 carboxylic acids, ethylene glycol diesters of C1-C30 carboxylic acids, propylene glycol monoesters of C1-C30 carboxylic acids, propylene glucol diesters of C1-C30 carboxylic acids, C1-C30 carboxylic acid monesters and polyesters of sugars, polydialky
  • oil materials generally having low solubility in water, generally less than about 1% by weight at 25degree C.
  • suitable oil components include, but are not limited to, the following materials. Some of these materials are further described in U.S. Pat. No. 4,919,934, to Deckner et al., issued Apr. 24, 1990.
  • Mineral oil which is also known as petrolatum liquid, is a mixture of liquid hydrocarbons obtained from petroleum. See The Merck Index, Tenth Edition, Entry 7048, p. 1033 (1983) and International Cosmetic Ingredient Dictionary, Fifth Edition, vol. 1, p. 415-417 (1993).
  • Petrolatum which is also known as petroleum jelly, is a colloidal system of nonstraight- chain solid hydrocarbons and high-boiling liquid hydrocarbons, in which most of the liquid hydrocarbons are held inside the micelles. See The Merck Index, Tenth Edition, Entry 7047, p. 1033 (1983); Schindler, Drug. Cosmet. Ind., 89, 36-37, 76, 78-80, 82 (1961); and International Cosmetic Ingredient Dictionary, Fifth Edition, vol. 1, p. 537 (1993).
  • Straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms are useful herein.
  • these hydrocarbon materials include dodecane, isododecane, squalane, cholesterol, hydrogenated polyisobutylene, docosane (i.e. a C.sub.22 hydrocarbon), hexadecane, isohexadecane (a commercially available hydrocarbon sold as PermethyLRTM. 101A by Presperse, South Plainfield, N.J.).
  • C7-C40 isoparaffins which are C7-C40 branched hydrocarbons.
  • Useful oils include C1-C30 alcohol esters of C1-C30 carboxylic acids and of C2-C30 dicarboxylic acids, including straight and branched chain materials as well as aromatic derivatives. Also useful are esters such as monoglycerides of C1-C30 carboxylic acids, deglycerides of C1-C30 carboxylic acids, triglycerides of C1-C30 carboxylic acids, ethylene glycol monoesters of C1-C30 carboxylic acids, ethylene glycol diesters of C1-C30 carboxylic acids, propylene glycol monoesters of C1-C30 carboxylic acids, and propylene glycol diesters of C1-C30 carboxylic acids.
  • Straight chain, branched chain and aryl carboxylic acids are included herein. Also useful are propoxylated and ethoxylated derivatives of these materials.
  • Nonlimiting examples include diisopropyl sebacate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, myristyl propionate, ethylene glycol distearate, 2-ethylhexyl palmitate, isodecyl neopentanoate, C.sub.12-15 alcohols benzoate, di-2- ethylhexyl maleate, cetyl palmitate, myristyl myristate, stearyl stearate, cetyl stearate, behenyl behenrate, dioctyl maleate, dioctyl sebacate, diisopropyl adipate, cetyl octanoate, diisopropyl dilinoleate, ca
  • esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties. Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature.
  • liquid esters include: glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated), the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoletate, sucrose hexaoleate, sucrose hepatoleate, sucrose octaoleate, and mixtures thereof.
  • solid esters examples include: sorbitol hexaester in which the carboxylic acid ester moieties are palmitoleate and arachidate in a 1:2 molar ratio; the octaester of raffinose in which the carboxylic acid ester moieties are linoleate and behenate in a 1:3 molar ratio; the heptaester of maltose wherem the esterifying carboxylic acid moieties are sunflower seed oil fatty acids and lignocerate in a 3:4 molar ratio; the octaester of sucrose wherem the esterifying carboxylic acid moieties are oleate and behanate in a 2:6 molar ratio; and the octaester of sucrose wherein the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1:3:4 molar ratio.
  • a preferred solid material is sucrose polyester in which the degree of esterification is 7-8, and in which the fatty acid moieties are C18 mono- and/or di-unsaturated and behenic, in a molar ratio of unsaturates:behenic of 1:7 to 3:5.
  • a particularly preferred solid sugar polyester is the octaester of sucrose in which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety in the molecule.
  • the ester materials are further described in, U.S. Pat. No. 2,831,854, U.S. Pat. No. 4,005,196, to Jandacek, issued Jan. 25, 1977; U.S. Pat. No. 4,005,195, to Jandacek, issued Jan.
  • Silicones such as polydialkylsiloxanes, polydiarylsiloxanes, polyalkarylsiloxanes, and cyclomethicones having 3 to 9 silicon atoms are useful oils. These silicones include both volatile and nonvolatile materials. These silicones are disclosed in U.S. Pat. No. 5,069,897, to Orr, issued Dec. 3, 1991.
  • the polyalkylsiloxanes include, for example, polyalkylsiloxanes with viscosities of from about 0.5 to about 100,000 centistokes at 25 degree C.
  • polyalkylsiloxanes include the polydimethylsiloxanes, which are also known as dimethicones, nonlimiting examples of which include the Vicasil.RTM. series sold by General Electric Company and the Dow Corning.RTM. 200 series sold by Dow Corning Corporation.
  • Specific examples of polydimethylsiloxanes useful as emollients herein include Dow Corning.RTM. 200 fluid having a viscosity of 0.65 centistokes and a boiling point of 100 degree C, Dow Corning.RTM. 225 fluid having a viscosity of 10 centistokes and a boiling point greater than 200 degree C, and Dow Corning.RTM.
  • Cyclic polyalkylsiloxanes useful herein include those corresponding to the general chemical formula [SiR2 ⁇ 0]n wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and n is an integer from about 3 to about 9, more preferably n is an integer from about 3 to about 7, and most preferably n is an integer from about 4 to about 6.
  • R is an alkyl group
  • R preferably R is methyl or ethyl, more preferably methyl
  • n is an integer from about 3 to about 9
  • preferably n is an integer from about 3 to about 7
  • most preferably n is an integer from about 4 to about 6.
  • R is methyl
  • these materials are typically referred to as cyclomethicones.
  • Commercially available cyclomethicones include Dow Corning.degree.
  • materials such as trimethylsiloxysilicate, which is a polymeric material corresponding to the general chemical formula [(CH.sub.2).sub.3 ].sub.x [SiO.sub.2 ]y, wherein x is an integer from about 1 to about 500 and y is an integer from about 1 to about 500.
  • a commercially available trimethylsiloxysilicate is sold as a mixture with dimethicone as Dow Corning.RTM. 593 fluid.
  • dimethiconols which are hydroxy terminated dimethyl silicones.
  • Commercially available dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g. Dow Corning.RTM.1401, 1402, and 1403 fluids).
  • polyalkylaryl siloxanes with polymethyphenyl siloxanes having viscosities from about 15 to about 65 centistokes at 25 degree C being preferred. These materials are available, for example, as SF 1075 methylphenyl fluid (sold by General Electric Company) and 556 Cosmetic Grade phenyl trimethicone fluid (sold by Dow Corning Corporation).
  • Vegetable oils and hydrogenated vegetable oils are also useful herein.
  • examples of vegetable oils and hydrogenated vegetable oils include safflower oil, caster oil, coconut oil, cottenseed oil, menhaden oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, hydrogenated safflower oil, hydrogenated caster oil, hydrogenated coconut oil, hydrogenated cottenseed oil, hydrogenated menhaden oil, hydrogenated palm kernel oil, hydrogenated palm oil, hydrogenated peanut oil hydrogenated soybean oil, hydrogenated rapeseed oil, hydrogenated linseed oil, hydrogenated rice bran oil, hydrogenated sesame oil, hydrogenated sunflower seed oil, and mixtures thereof.
  • polypropylene glycols C4-C20 alkyl ethers of polypropylene glycols, Cl- C20 carboxylic acid esters of polypropylene glycols, and di-C8-C30 alkyl ethers.
  • Nonlimiting examples of these materials include PPG-14 butyl ether, PPG-15 stearyl ether, PPG-9, PPG-12, PPG-15, PPG-17, PPG-20, PPG-26, PPG-30, PPG-34, dioctyl ether, dodecyl octyl ether, and mixtures thereof.
  • the complexes that are believed to be formed from the amphoteric, anionic, and cationic surfactants of the present invention are preferably preprepared by the following procedures.
  • the amphoteric and anionic surfactants are first combined in aqueous solution, thereby forming what is believed to be a dispersion of the complex between these two materials.
  • This dispersion is then combined directly with an aqueous solution of the cationic surfactant.
  • this dispersion can be added directly to a composition already containing the desired cationic surfactant.
  • the present invention also relates to methods wherein an effective amount of the composition of the present invention is applied to the skin.
  • These compositions are useful for conditioning and treating dry skin and for providing active ingredients to the skin.
  • a wide range of quantities of the compositions of the present invention can be used. Quantities which are typically applied can range from about 0.1 mg/cm2 to about 25 mg/cm2.
  • the compositions of the present invention are useful for personal cleansing, especially for cleansing of the face and neck areas.
  • a suitable or effective amount of the cleansing composition is applied to the area to be cleansed.
  • a suitable amount of the cleansing composition can be applied via intermediate application to a washcloth, sponge, pad, cotton ball or other application device.
  • the area to be cleansed can be premoistened with water.
  • the compositions of the present invention can be combined with water during the cleansing process and rinsed-off from the skin.
  • the composition can be used along and wiped-off from the skin using a pad, cotton ball, tissue, or other like device.
  • the cleansing process is typically a two-step process involving application of the composition followed either by rinsing of the produce with water or wiping without the use of water.
  • an effective amount of composition to be used will depend upon the needs and usage habits of the individual.
  • Example 1 A leave-on lotion composition containing benzoyl peroxide (0.1-10.0%) is prepared by combining the following ingredients using conventional mixing techniques.
  • Phase A ingredients are heated with stirring to about 75 degree C.
  • Phase B ingredients are heated with stirring to about 75 degree C.
  • Phase B is then added to Phase A with mixing.
  • Phase C is added with mixing.
  • the mixture is cooled to 35 degree C.
  • the active lipoic acid derivative, synthesized as described in this invention is added with mixing.
  • the Phase E ingredients are combined and added to the remaining mixture with stirring.
  • the resulting leave-on composition is useful for preventing and treating acne (including rosacea) while being mild to the skin.
  • a composition is prepared in which the cetyl dimethyl betaine is replaced with stearyl dimethyl betaine.
  • Example 2 A personal cleanser composition containing either salicylic acid (0.1-20.0%) or azelaic acid (0.1-20.0%) is prepared by combining the following ingredients using conventional mixing techniques.
  • the Phase A ingredients are heated with stirring to about 75degree C.
  • the Phase B ingredients are heated with stirring to about 75 degree C.
  • Phase B is then added to Phase A with mixing.
  • the oxidized polyethylene beads are added slowly with mixing to prevent agglomeration.
  • the fragrance is added with mixing.
  • the mixture is cooled to 35 degree C.
  • the Phase D ingredients are combined and added to the remaining mixture with stirring (typically these ingredients are available as aqueous solutions and are combined as such).
  • the resulting cleansing composition is useful for preventing and treating skin damage induced by sunlight (UV radiation) and for cleansing the skin.
  • a composition is prepared in which the sodium lauryl sulfate is replaced with sodium lauroyl isetheonate.
  • Example 3 A personal cleanser is prepared by combining the following ingredients using conventional mixing techniques.
  • Phase A ingredients are heated with stirring to about 75 degree C.
  • Phase B ingredients are heated with stirring to about 75 degree C.
  • Phase B is then added to Phase A with mixing.
  • fragrance and menthol are added with mixing.
  • the mixture is cooled to 35 degree C.
  • Phase D ingredients are combined and added to the remaining mixture with stirring (typically these ingredients are available as aqueous solutions and are combined as such).
  • the resulting cleansing composition is useful for cleansing the skin, for preventing or ameliorating skin dryness and wrinkle formation in the skin, for preventing thinning of the skin, for increasing the thickness, hydration and pliability of the skin, and for inhibiting the aging process in skin.
  • a composition is prepared in which the menthol is eliminated and the water level is correspondingly increased.
  • composition is prepared in which the sodium lauryl sulfate is replaced with sodium lauroyl isethionate.
  • Example 4 A leave-on cream composition is prepared by combined the following ingredients using conventional mixing techniques. Ingredients Weight Percent
  • Phase A ingredients are heated with stirring to about 75 degree C.
  • Phase B ingredients are heated with stirring to about 75 degree C. Phase B is then added to Phase A with mixing. Next the fragrance is added with mixing. Next, the mixture is cooled to 35 degree C. In a separate vessel, the Phase D ingredients are combined and added to the remaining mixture with stirring (typically these ingredients are available as aqueous solutions and are combined as such).
  • the resulting leave-on cream is useful for conditioning the skin and provides a soft/smooth skin feel, for preventing or ameliorating skin dryness, for preventing thinning of the skin, for increasing the thickness, hydration and pliability of the skin, and for inhibiting the aging process in skin.
  • a composition is prepared in which the sodium lauryl sulfate is replaced with sodium lauroyl isethionate.
  • Example 5 A leave-on lotion composition containing a lipoic acid derivative is prepared by combining the following ingredients using conventional mixing techniques.
  • Phase A ingredients are heated with stirring to about 75 degree C.
  • Phase B ingredients are heated with stirring to about 75 degree C. Phase B is then added to Phase A with mixing. Next Phase C is added with mixing. Next the Phase D ingredients are added with mixing. Next, the mixture is cooled to 35 degree C. hi a separate vessel, the Phase E ingredients are combined and added to the remaining mixture with stirring.
  • the resulting leave-on composition is useful for preventing treating acne while being mild to the skin and providing a soft/smooth skin feel, and for preventing or ameliorating skin dryness and wrinkle formation in the skin, for preventing thinning of the skin, for increasing the thickness, hydration and pliability of the skin, and for inhibiting the aging process in skin.
  • a composition is prepared in which the sodium lauryl sulfate is replaced with sodium lauroyl isethionate.
  • compositions of the present invention demonstrate the typical use of the protective skin composition of the present invention in skin care and over the counter (OTC) pharmaceutical products. These formulations are listed only as examples of the types of compositions that could be used, and are not all encompassing of the possible uses of the technology in skin care and OTC pharmaceutical products. One skilled in the art of formulation will readily envision other possible uses for this technology, and the invention is not restricted the use of the formulations listed below. All ingredients of the formulations listed below are shown in percentage by weight (% w/w). The following is a general formula for ligand formulations of the composition.
  • composition is useful for preventing treating acne (including rosacea) while being mild to the skin and providing a soft/smooth skin feel, and for preventing or ameliorating skin dryness and wrinkle formation in the skin, for preventing thinning of the skin, for increasing the thickness, hydration and pliability of the skin, and for inhibiting the aging process in skin.
  • the following oil-in-water formulation was developed as a moisturizing lotion for the skin.
  • the following is a general formulation for a moisturizing soap bar.
  • Buffering Agents 1.00-3.00 Humectants and Skin Conditioning Agents 0.50-5.00
  • Vitamin E Acetate 0.05-30.00 Magnesium Ascorbyl Phosphate 0.0001-3.00
  • the above moisturizing facial soap composition provides improved skin feel useful for cleansing, conditioning, desquamating the skin, for relieving dry skin and alleviating the appearance of aging.
  • the 4-substituted-l,2-dithiolanes are an interesting class of relatively unexplored compounds, potentially useful for a variety of applications related to their similarity to 3- substituted-l,2-dithiolanes (e.g. lipoic acids ⁇ ).
  • 3- substituted-l,2-dithiolanes e.g. lipoic acids ⁇ .
  • Provided in Case 1 are structures of isolipoic acids, while lipoic acid derivatives are shown in Case 2. Both classes of compoimds exemplified by Case 1 and 2 are useful for dermatological, pharmaceutical, cosmeceutical, or cosmetic applications.
  • R and Rj both attach to the same carbon atom to form a 1,3-dithiane ring, in particular, thioketals are suggested such as where the connection is C(Me) 2 , a dimethylketal otherwise known as a 2,2-dimethyI-l,3-dithiane.
  • R is H, or an acyl group COR .
  • Ri is H, or an acyl group COR ⁇ .
  • R 2 , R 3 and R4 any combination of H, heterosubstituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or unsubstituted normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings.
  • NHR 15 NR ⁇ 5 R ⁇ 6 , OR ⁇ S , SR 15 .
  • these groups can contain antioxidant molecules linked through ester or other carbonyl bonds (e.g. ascorbic acid, retinol, vitamin E, vitamin D, hydroquinone, di(t- butylated)hydroxytoluene BHT, t-butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein).
  • n 0 - 8 carbons
  • X H, OH, or R 5 , substituted -OR ⁇ , -SR ⁇ , -NRsR 7 , -PO(OR6) 2 ; -SORg, -SO 2 R 6 , - SO 2 NR 6 R 7 , COOH; COORg; CONR 6 R 7 , F, CI, Br, substituted and unsubstituted aryl, heteroaryl, arylalkyl, alkylheteroaryl, heterocyclic, saturated and unsaturated rings.
  • SO 2 NR 9 Rio COOH; COOR 9 ; CONR 9 R )0 , F, CI, Br, substituted and unsubstituted aryl, heteroaryl, arylalkyl, alkylheteroaryl, heterocyclic, saturated and unsaturated rings.
  • Z H, OH, OR n , NH 2 , NHR ⁇ 2 , NR ⁇ 2 R ⁇ 3 , SR ⁇ ; normal or branched hydrocarbons from Cl- C20, aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings.
  • Z can be other antioxidant molecules linked through ester or other carbonyl bonds (e.g.
  • ascorbic acid retinol
  • vitamin E vitamin D
  • hydroquinone di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein).
  • a silicon version of Meldrums Acid, 11, should be straightforward to prepare from malonic acid itself, and is expected to effect S displacement of bromides 7.
  • conversion of malonate acids into mixed anhydrides allows for borohydride reduction to alcohol 9, again without affecting the ester moiety.
  • dialkyl malonic acid NaH, THF; then 13; b) L1A-H4, THF, 0 C; or Na, EtOH; c) O3, MeOH; then add CH2CI2, Ac2 ⁇ , Et3N; d) CH3SO2CI, pyridine; then NaSH; e) NaOH, O2, EtOH; f) NaH, THF, 13; g) (RO) n AlH m Li, THF or NaBH4, THF; or L-AIH4, THF; h) MeOH, Lewis Acid.
  • Oxidation of the olefinic group of 15 with ozone gives an intermediate methoxy-hydroperoxyacetal, itself capable of in situ oxidative elimination to a methyl ester upon treatment with acetic anhydride and base.
  • lactones may be formed in the process and recycled back to diol ester 9 by alcoholysis (e.g. excess MeOH, catalyst).
  • An alternative to the Schreiber oxidation would be to block the hydroxyl groups of 15 prior to oxidation, and use a more vigorous oxidative workup to generate the required acid group.
  • a useful protection scheme is a silicon-protecting group, such as the tert- Butyldimethylsilyl moiety (TBS group), installed via TBSCl, to give 18.
  • TBS group tert- Butyldimethylsilyl moiety
  • oxidation on the intermediate ozonides or other post ozonolysis intermediates can proceed without interference from the primary hydroxyl groups, and in situ oxidation can then provide the acid 19.
  • a Cr(VT) oxide workup such as by adding Jones reagent to the ozonide, a reaction precedented to furnish the acid directly.
  • the oily properties of an antioxidant such as Vitamin E (or alpha-tocopherol) can have problematical side effects upon topical application since the occurrence of acne is promoted by oily skin.
  • the water-soluble ⁇ -hydroxyisolipoates would not suffer from such a drawback.
  • the chiral R or S versions of 23 can be readily prepared from 19 as shown in Scheme 6. Conversion of 19 to the 5R or 5S-oxazolidinones 24 by standard methods, generation of the enolate 24a, followed by oxygenation should provide the ⁇ -hydroxyamides 25. Concurrent, careful transesterification with chiral auxiliary removal should be achievable with NaOMe to regenerate the methyl
  • Both group of the ⁇ -hydroxyacid can be simultaneously blocked by formation of an acetal derivative such as a benzylidine or acetonide 26.
  • a second approach to protection-deprotection in this system involves derivatization of the alcohol of 25 as an acetate or related carbonyl species, leaving the auxiliary in place until later.
  • acetylation of 25 is shown in Scheme 8, giving 30, which can be followed by desilylation to provide 31.
  • the desilylation might be performed with TBAF in THF, and if these fairly basic conditions were to affect some degree of racemization, one might effect deprotection under mildly acidic conditions with HF, or HF yridine or HF'triethylamine.
  • Hydrolysis of the acetate concurrently with auxiliary removal if done in the presence of oxygen, is expected to provide the dithiolane- ⁇ -hydroxyacids 23.
  • corresponding pyruvates are readily prepared from the ⁇ -hydroxyacids by oxidation, for which racemic hydroxyacids are clearly sufficient.
  • treatment of hydroxyacid products with activated sulfur reagents such as those prepared under Swern conditions should provide keto-acids 36.
  • dianion quench with oxygen will give a hydroperoxyacid intermediate. If the intermediate is captured with acetic anhydride, under basic conditions it should undergo facile ⁇ -elimination to afford the pyruvate derivative 33 directly. In this case, manipulation of the silyl ethers as before should ultimately provide the desired product 36.
  • Lipoamides represent more bioavailable versions of lipoic acid, readily hydrolyzed topically or systemically by amidases to the corresponding acids.
  • any of the above acid products can be delivered either as the amide or ester prodrug forms.
  • the esters are frequently part of the reaction schemes and simply omitting the ester hydrolysis step should be sufficient to gain access to the dithiolane-ester products.
  • simple amidation chemistry on free acid products should be adequate to give the amides as shown in Scheme 10.
  • An example of this later case might be conversion of the acid 37 to the hydroxysuccinamide ester 40, followed by addition of anhydrous ammonia, or an ammonia equivalent such as TMS-NH2 to provide 44.
  • alkyl substituted amines or diamines can be used such as N,N-dimethylethylenediamine, giving 43.
  • the later amide-type applied to lipoic acid itself, furnishing "lipoic acid plus” is a particularly bioavailable derivative with reported enhanced cellular accumulation properties and neuroprotective effects, which should be useful when applied in these cases.
  • ⁇ Hydroxy-substituted examples are amenable to this chemistry providing that the hydroxyl group is suitably protected.
  • the silyl-acid 39 should undergo activation as before to provide 42, and reaction with N,N-dimethylethylenediamine is expected to lead to the silyl-amide 45; deprotection of which should then give 46, a bioavailable, prodrug of an ⁇ -hydroxyacid-dithiolane.
  • the ⁇ -hydroxyacid analogs of isolipoic acid or lipoic acid, such as 38 can be furnished as the correspondmg esters from syntheses outlined in previous schemes (e.g., by air oxidation of 10 or 22) , or can be obtained by esterification of dithiolane-acids such as 1-6, 23, 36, or 37.
  • Ethyl esters would be attractive for systemic drugs, since metabolism would liberate ethanol.
  • the NHOS ester 40 could be treated with alcohol and base to afford 52 as well.
  • N-hydroxysuccinamide, CH2CI2, pyridine, DCC; b) R"NH2, CH2CI2; c) when X H or OSi(R')3: N-hydroxysuccinamide, CH2CI2, 3R"NH2; then DCC; d) N-hydroxysuccinamide, CH2CI2, DMAP, pyridine, DCC; e) Zn, (R ⁇ CO)2 ⁇ ; f) R2OH, pyridine; g) NaHC0 3 , MeOH, HOH; h) TBAF, THF; i) pyridine, DCC, CH2CI2; then R2OH; j) R2OH, pyridine.
  • An attractive alternative is to dimerize the ⁇ -hydroxyacid itself to a l,4-dioxan-2,5-dione, such as 48. In vivo metabolic hydrolysis back to the ⁇ -hydroxyacid is expected.
  • Hydroxamic acid analogs of lipoic and isolipoic acid e.g.
  • MMP's matrix metalloproteinases
  • MMP- 1 collagenases 1
  • MMP13's matrix metalloproteinases
  • a typical MMP antagonist has a ⁇ -isobutyl substituent such as for inhibitor 56:
  • the ⁇ -isobutyl group in 57 could be introduced via conjugate addition of isobutyl magnesium cuprate to the corresponding chiral acrylate 58 as outlined in Scheme 11.
  • introduction of a double bond to provide the ⁇ , ⁇ -unsaturation in 58 is straightforward.
  • Capture of the enolate of 24 with PhSSPh, oxidation and in situ elimination should give the trans-olefin 58.
  • PhSO2SPh could be used in place of PhSSPh/oxidation.
  • Another alternative involves the use of PhSeCl in place of the above sulfur reagents.
  • the enolate could be quenched and the resulting oxazolidinone 63 could be converted from TBS ethers to the dithiol 64 as outlined in previous Schemes: fluoride treatment to remove the silyl groups; mesylation to activate the alcohol moieties, and displacement with appropriate thiol (e.g. NaSH) should furnish dithiol 64, With dithiol in hand, the oxazolidinone could be replaced by hydroxylamine to give the hydroxamic acid 57 after oxidation of the dithiol to the dithiolane.
  • fluoride treatment to remove the silyl groups
  • mesylation to activate the alcohol moieties
  • displacement with appropriate thiol e.g. NaSH
  • the oxazolidinone could be replaced by hydroxylamine to give the hydroxamic acid 57 after oxidation of the dithiol to the dithiolane.
  • acylated thiols are of interest as prodrugs of highly activated antioxidant dithiols, means of capturing the intermediate dithiols as acyl esters are of utility.
  • the dithiol acid 65 would be produced.
  • Treatment of 65 with excess acetic anhydride, pyridine should lead to formation of a triacetate-mixed anhydride, which if quenched with hydroxylamine, should give target 67.
  • the triacetate 67 is a prodrug of 57 in that once the acetates have been cleaved by esterases; air oxidation of the dithiol is expected to give the dithiolane 57.
  • 57 are itself a potent antioxidant target.
  • dithiol 61 can be processed via 66 (Scheme 11) to the ⁇ -hydroxylated- hydroxamate 68, or directly to the dithiolane 62.
  • the molecule 68 is designed to have multiple desirable pharmaceutical and cosmetic properties: It should be a long acting topical or systemic agent with powerful antioxidant properties; it should have collagen-protective, antagonist activity towards MMP-1, -2, -9 and -13; the combination of antioxidant properties and MMP antagonism should be synergistic in protecting tissues, particularly facial skin; it should be metabolized to 62, itself possessed of potent activity as described above; metabolism of hydroxamic acids provides carboxylic acids, which themselves should possess binding affinity to MMP's; and the ⁇ - hydroxycarboxylic acid metabolite should have exfoliative properties by analogy to commercially available hydroxy-acids such as glycolic acid.
  • combination cremes for which synergism is important present multiple problems: for example, the individual components may possess different residency times in the tissues; each component may therefore have different formulation requirements which may not be mutually compatible; and finally, the cost of expensive formulation may outweigh the admitted advantage of combining 2 natural, non-FDA controlled substances with a single, known, FDA-controlled MMP inhibitor.
  • structures such as 79, 85, and 93-96 can be replaced or converted to prodrug dimers analogous to 48 (Scheme 10).
  • Examples include compounds 97 and 98:
  • R, S or r ⁇ c-lipoic acid to the skin, the eye, and other organs is desirable as a means of targeting its antioxidant, regulatory and enzymatic activities, and as a means of prolonging its actions for sustained medicinal, dermatological or cosmetic use.
  • One such approach is to construct suitable prodrugs or provitamins of dihydrolipoic acid such as neutral hydrophobic esters or amide derivatives of the carboxylate group together with the thiol modifications: thioesters, thiocarbonates, thioamides, etc., in which the penetration into the various layers of the skin can be fine tuned by structural modification. This is shown in Figure 1, which shows the Provitamin Approach to Slow Release of Antioxidant Thiols of Dihdyrolipoic Acid Via the Corresponding Acyl Derivatives.
  • Lipoic acid can be reduced to dihydrolipoic acid 110, a more potent but less stable antioxidant that reacts with air or other oxidants to revert to lipoic acid, or can be esterified, for example, to provide ethyl lipoate 112.
  • Dihydrolipoic acid 110 can be simultaneously thioesterified whilst the carboxylate group is converted to the active ester with, as a representative example, butyryl chloride and pyridine.
  • the reactive intermediate active ester 111 can then be reacted in situ with alcohols to give esters 113, amines to give amides 114, or thiols to give thioester 115.
  • Pn p the permeability coefficient for the SC
  • J m maximum flux
  • S oct the octanol solubility
  • K oct the octanol/water partition coefficient
  • MW the molecular weight
  • Log K oc - is more recognizable as the "LogP" value, oftentimes calculated empirically by software programs (e.g. ChemDraw). For example, for compound 115 with MW of 420.7 and a calculated LogP of 5.77, the LogP ⁇ ip is calculated to be 5.35; while on the other hand, for ethyl lipoate 112, the LogP ⁇ ip is 1.64. To some extent, the selection of a LogPup range depends on other factors such as flux rate, enzymatic reactivity, and achieving a balance in LogP ⁇ ip reflective of the differing environments between the lipophilic SC and more aqueous VE. In general, selection of lower melting compounds with intermediate LogP values, perhaps with chiral or branched esters, and appropriate formulation strategies will afford the best approach to slow delivery of long-acting dihydrolipoic acid and lipoic acid. 26
  • DHLA dihydrolipoic acid
  • LA lipoic acid
  • thiocarbonates 118 and 119 are provided in Scheme 16.
  • antioxidants work together synergistically to provide a barrier to radical damage to organs and other tissues.
  • vitamins work together such as E, C, A, CoQio, lipoic acid, etc., with trace selenium to provide redox balance and an overall antioxidant state in tissue.
  • covalently linked antioxidants can provide a means of modification of physical properties to enhance delivery to specific organs or tissues. For example, linkage of the carboxyl group of dihydrolipoic or S,S'-diacyldihydrolipoic acid to ascorbic acid should provide a mutual-provitamin, as shown in Scheme 18.
  • the most acidic hydroxyl group of ascorbic acid may react more readily with one equivalent of base and an active ester to furnish the lipoate ester 131.
  • Reduction to the dithiol with borohydride affords 132, and then reaction with a variety of electtophiles as outlined above for lipoate derivatives gives 133.
  • R and Ri together form a single bond between the two sulfurs to give a 1,2-dithiolane ring.
  • R and Ri both attach to the same carbon atom to form a 1,3-dithiane ring, in particular, thioketals are suggested such as where the connection is C(Me) 2 , a dimethylketal otherwise known as a 2,2-dimethyl-l,3-dithiane.
  • R is H, or an acyl group CO t .
  • R] is H, or an acyl group COR
  • H any combination of H, heterosubstituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or unsubstituted normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings. Also contained are NHR 15 , NR ⁇ 5 R ⁇ 6 , OR 15 , SR ]5 .
  • R, R 1 are C0CH 3
  • R, R 4 are CH 2 0C0CH 3
  • retinol can be linked to lipoic acid to give the ester or other prodrugs as shown in Scheme 19.
  • Use of retinol to esterify and transform lipoic acid follows by direct analogy to previous transformations, except that some care must be exercised to protect the retinol and subsequent derivatives from air and light until they can be suitably formulated in a stable medium.
  • the lipoate ester of retinol 136 is useful in itself, as esterase cleavage leads to retinol and lipoic acid.
  • Retinol is the biochemical precursor to retinal and retinoic acid; while lipoic acid can be oxidized or reduced to dihydrolipoic acid.
  • 136 can be reduced to the dithiol 137, and derivatized with electrophiles (e.g. acid chlorides, anhydrides, mixed anhydrides, alkyl halides and so forth) to furnish 138.
  • electrophiles e.g. acid chlorides, anhydrides, mixed anhydrides, alkyl halides and so forth
  • these chemistries teach one the concept of derivatization of other antioxidants or compounds of interest with lipoic acid, and how the resulting adduct proVit-LA (e.g. 131) is reduced and derivatized to furnish pro-mutual-vitamins such as VitC-DHLA (e.g. 133).
  • proVit-LA e.g. 131
  • VitC-DHLA e.g. 133
  • Figure 3 shows examples of other antioxidants that can be linked to LA or derivatives of DHLA.
  • R ⁇ COCH 3 ; CH 2 OCOCH 3 , etc.
  • Burns JA Whitesides GM. Predicting the stability of cyclic disulfides by molecular modeling: effective concentrations in thiol-disulfide interchange and the design of strongly reducing dithiols. J. Am. Chem. Soc. 1990; 112:6296-303.
  • Harpp DN Gleason JG. Organic sulfur chemistry. III. Chemistry of small-ring sulfur compounds. Thietanes and 1,2-dithiolanes. J. Org. Chem. 1970;35:3259-63. 14.
  • Singh R Whitesides GM. Comparisons of rate constants for thiolate-disulfide interchange in water and in polar aprotic solvents using dynamic proton NMR line shape analysis.
  • S-nitrosothiols can exert a potent relaxant effect, mediated both by guanylate cyclase, upon vascular smooth muscle and non-vascular smooth muscle located in the airway, gastrointestinal, and urogenital tract, such as the corpora cavernosa and vestibular tissues in men and women. Additionally, S-nitrosothiols may be used to alleviate smooth muscle contraction and spasm. S-nitrosothiols also increase the binding affinity between hemoglobin and oxygen, improve hemoglobin-oxygen binding, and oxygen transport to bodily tissues. Thus, S-nitrosothiols may be used for the treatment or prevention of disorders associated with relation of smooth muscle, such as angina pectoris, respiratory disorders, bladder dysfunction, premature labor and impotence. As shown in Figure 4, the Biochemical Pathway for the Reduction of Nitrate and Nitrite Esters to Nitric Oxide (NO), are known.
  • NO has an important vasodilatory role in cardiovascular and other tissues.
  • erectile tissue leads to eradication of erectile dysfunction, drugs effecting production of NO are clinically important.
  • Sildenaf ⁇ l (ViagraTM), a semiselective inhibitor of the phosphodiesterase (PDE) isoenzyme-5, is an important new drug for sexual dysfunction in man. Its efficacy in women is under investigation.
  • PDE phosphodiesterase
  • its systemic delivery and incomplete PDE isoform selectivity may cause life-threatening cardiovascular vasodilation and serious adverse sensory disturbances, e.g. blindness in retinitis pigmentosa.
  • the delay in achieving the desired effect after oral absorption is less than optimal considering the intended use.
  • S-nitrosothiols can be designed to effectively deliver NO equivalents to tissues deep to the epidermis, such as the corpora cavernosum in the penis and glans in men, and the clitoris, clitoral corpora cavernosa, the vestibule and vestibular erectile structures in women.
  • Drugs that deliver NO on demand to the site of action are RSNO formulations for topical application just prior to sexual activity, allowing for transdermal absorption and release of NO within the crucial tissues involved in the vasodilatory action (erection of penis or clitoris). This type of drug is expected to be highly potent.
  • the desired by-product of NO release is one which is a non-odoriferous thiol.
  • various contraceptive devices could be charged or applied with these formulations.
  • Spermacidal jellies, condom lubricants applied to the internal or external surfaces, or both, and the like are a few examples of barrier containing devices containing the NO precursor.
  • compositions of NO are carrier molecules such as prodrug forms of lipoic acid (Case I) or glutathione (Case II).
  • carrier molecules such as prodrug forms of lipoic acid (Case I) or glutathione (Case II).
  • Case I prodrug forms of lipoic acid
  • Case II glutathione
  • R 5 - R ⁇ 3 alkyl, aryl, alkylaryl, alkenyl, heteroaryl, substituted .aryl and heteroaryl Schema
  • Topical dermatological uses relate to treatment of conditions or diseases that respond to enhanced smooth muscle relaxation, hi one aspect, this relates to the treatment of diseases or conditions involving vascular (smooth muscle) relaxation, resulting in increased blood flow and enhanced tissue oxygenation and tissue vitality.
  • diseases or conditions involving vascular (smooth muscle) relaxation resulting in increased blood flow and enhanced tissue oxygenation and tissue vitality.
  • These include angina pectoris (includes sublingual application), promotion of healing of ulcers and sores via increased oxygenation and blood flow in situ, amelioration of diabetic neuropathy, diabetic ulcers, ischemic ulcers, venous (e.g. stasis) ulcers and pressure sores; promotion of hair follicle survival through enhanced blood suly to the scalp in alopecia through increased blood flow to scalp.
  • this invention relates to relaxation of bronchial and bronchiolar smooth muscle, as in the treatment of respiratory disorders such as bronchospasm, bronchoconstive disease, reactive airway disease and chronic obstructive pulmonary disease (include transpulmonary application); relaxation of smooth muscles of the bladder in the treatment of bladder dysfunction; relaxation of smooth muscles of the cervix and uterus to promote cervical dilation and relaxation during childbirth delivery; relaxation of smooth muscles and of the vasculature and corpus cavernosum in men, and corpora cavernosa and vestibular structures in women, to promotion of tumescence, engorgement and erection of sexual urogenital structures to alleviate impotence.
  • respiratory disorders such as bronchospasm, bronchoconstive disease, reactive airway disease and chronic obstructive pulmonary disease (include transpulmonary application)
  • relaxation of smooth muscles of the bladder in the treatment of bladder dysfunction relaxation of smooth muscles of the cervix and uterus to promote cervical dilation and relaxation during childbirth delivery
  • a first compound of this invention is disclosed as:
  • R and Rj together can form a single bond between the two sulfur atoms to give a 1,2-dithiolane ring;
  • R and Ri can both attach to the same carbon atom to form a 1,3-dithiane ring, in particular, thioketals are suggested such as where the connection is C(Me) 2 , a dimethylketal otherwise known as a 2,2-dimethyl-l,3-dithiane;
  • R can be H, or an acyl group -COR ;
  • R can be a -CH 2 OCOR-,.or -CH(R j )OCOR 4 ;
  • Rj can be H, or an acyl group -COR-j; Ri can be a -CHzOCOI , or -CHC j CO t ;
  • R j can be H, optionally substituted alkyl, branched alkyl, cycloalkyl, bi and tricycloalkyl and bi and tricycloalkenyl, alkenyl, allenyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, alkynyl, aryl, arylmethylenyl, arylethylenyl, heteroalkyl, heterocyclic, heteroaromatic, alkylheterocyclic, alkylheteroaryl.
  • Rj can be an ether OR 5 ; disubsituted amine NR 6 R ; ester COOR 8 ; aldehyde CHO; mono, di or unsubsituted amide CONR 9 R ⁇ 0 ; ketone COR ⁇ ; sulfide R 30 S-; sulfoxide R 3 ⁇ SO-; or sulfone R 32 SO 2 -.
  • an optional substituent can also be selected from the above group as well as the following: alcohol; mono, or unsubsituted amine NR5R 7 ; formate OCHO; formamide NRQCHO; acyl ester OCOR ⁇ 2 ; acyl carbonate OCOOR ⁇ 3 ; acyl carbamate OCONR ⁇ 4 R 15 ; acyl urea NR 16 CONR ⁇ R ⁇ 8 ; halides F, CI, Br, or I; nitro N0 2 ; nitroso, NO; hydrazide R ⁇ 9 NNR 20 R 2 ⁇ ; acyl hydrazide R 22 CONR 23 NR 2 R 25 ; diacyl hydrazide R 26 CONR 27 N 28 COR 29 ; sulfonamide R 33 R 34 NS0 2 -; sulfonamidyl R 35 NS0 2 R 36 ; disulfide R 37 SS- ; acyl thi
  • the optional substituent may be attached with R or S stereochemistry, or may be racemic. In other instances, the substituent may not be chiral.
  • These optional groups can contain antioxidant molecules linked through ester or other carbonyl bonds (e.g. ascorbic acid, retinol, vitamin E, vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t-butylatedhydroxyanisole BHA, t-butylhydroquinone
  • n 0 - 8 carbons
  • m 0 - 8 carbons
  • X can be H, OH, or R 5 , substituted -OR 6 , -SRg, - ReR ? , -PO(OR 6 ) 2 ; -SOR 6 , -S0 2 R 6 , -
  • Z H, OH, OR ⁇ , NHOH, NH 2 , NHR 12 , NR ⁇ R ⁇ 3 , SR 14 ; normal or branched hydrocarbons from C1-C20, aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings; Z can be other antioxidant molecules linked through ester or other carbonyl bonds (e.g.
  • Ro and R 5 - R 86 can be H, an alkyl, a branched alkyl, a cycloalkyl, a bicycloalkyl, a bicycloalkenyl, an alkenyl, an allenyl, a cycloalkenyl, an alkylcycloalkyl, an alkylcycloalkenyl, an alkynyl, an aryl, an arylmethylenyl, an arylethylenyl, a heteroalkyl, a heterocyclic, a heteroaromatic, an alkylheterocyclic, or an alkylheteroaryl.
  • a second compound is disclosed herein, having the formula
  • R and Ri together can form a single bond between the two sulfur atoms to give a 1,2-dithiolane ring;
  • R and Ri can both attach to the same carbon atom to form a 1,3-dithiane ring, in particular, thioketals are suggested such as where the connection is C(Me) 2 , a dimethylketal otherwise known as a 2,2-dimethyl- 1,3-dithiane;
  • R can be H, or an acyl group -COR 4 ;
  • R can be a -CH 2 OCOR,.or -CH(R j )OCOR.
  • Ri can be H, or an acyl group -COR 4 ;
  • R j can be H, optionally substituted alkyl, branched alkyl, cycloalkyl, bi and tricycloalkyl and bi and tricycloalkenyl, alkenyl, allenyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, alkynyl, aryl, arylmethylenyl, arylethylenyl, heteroalkyl, heterocyclic, heteroaromatic, alkylheterocyclic, alkyl
  • R j can be an ether OR 5 ; disubsituted amine NR ⁇ ;R 7 ; ester COOR 8 ; aldehyde CHO; mono, di or unsubsituted amide CONR 9 R ⁇ 0 ; ketone COR ⁇ ; sulfide R 30 S-; sulfoxide R 31 SO-; or sulfone R 32 S0 2 -.
  • an optional substituent can also be selected from the above group as well as the following: alcohol; mono, or unsubsituted amine NR 6 R 7 ; formate OCHO; formamide NRoCHO; acyl ester OCOR ⁇ 2 ; acyl carbonate OCOOR ⁇ 3 ; acyl carbamate OCONR 14 R ⁇ 5 ; acyl urea NR ⁇ 6 CONR 17 R 18 ; halides F, CI, Br, or I; nitro N0 2 ; nitroso, NO; hydrazide R ⁇ 9 NNR 20 R 2 i; acyl hydrazide R 22 CONR 23 NR 24 R 2 5; diacyl hydrazide R 26 CONR 27 NR 28 COR 29 ; sulfonamide R 33 R 34 NS0 2 -; sulfonamidyl R 35 NSO 2 R 36 ; disulfide R 37 SS-
  • the optional substituent may be attached with R or S stereochemistry, or may be racemic. In other instances, the substituent may not be chiral.
  • These optional groups can contain antioxidant molecules linked through ester or other carbonyl bonds (e.g.
  • n 0 — 8 carbons
  • m 0 — 8 carbons
  • X can be H, OH, or R 5 , substituted -OR 6 , -SR & -NR ⁇ R?, -PO R ⁇ ; -SOR 6 , -SO 2 R6, - SO 2 R6R 7 , COOH; COORg; CON ⁇ R?, -COR., F, CI, Br, substituted and unsubstituted aryl, heteroaryl, arylalkyl, alkyl
  • Ro and R 5 - R 86 can be H, an alkyl, a branched alkyl, a cycloalkyl, a bicycloalkyl, a bicycloalkenyl, an alkenyl, an allenyl, a cycloalkenyl, an alkylcycloalkyl, an alkylcycloalkenyl, an alkynyl, an aryl, an arylmethylenyl, an arylethylenyl, a heteroalkyl, a heterocyclic, a heteroaromatic, an alkylheterocyclic, or an alkylheteroaryl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is an alkoxyl or hydroxyl group -OR, wherein Re is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 1 5) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is an amine group -NR ⁇ ? , wherein R- and R 7 are members of a group consisting of hydrogen and optionally substituted (C 1 -C 15 ) hydrocarbons, or can together form a ring, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is OR, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 15 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfide or thiol group -SR ⁇ 8 , wherein R ⁇ is a member of a group consisting of hydrogen and optionally substituted ( - s) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfone or sulfoxide group -S(0) W R 6 , wherein R 6 is a member of a group consisting of hydrogen and optionally substituted ( -C15) hydrocarbons, w is an integer from 1 to 2, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfonamide group -S0 2 R R , wherein R 6 and R 7 are members of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a phosphonate group -PO(OR6) 2.
  • R 6 is a member of a group consisting of hydrogen and optionally substituted (C 1 - 5 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and
  • Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C Ci5)alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a carboxylate or ester group -C0 2 R ⁇ .
  • Re is a member of a group consisting of hydrogen and optionally substituted (C 1 - 5 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and
  • Z is ORo, wherein o is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a carboxylate or ester group -COR;, wherein Re is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 1 5) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C_-C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a halogen group -F, -CI or -Br, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is OR), wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl .
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a substituted or unsubstituted aryl, heteroaryl, arylalkyl, alkylheteroaryl, heterocyclic, saturated and unsaturated ring or ring bearing group -R- 8 , wherein the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is OR , wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • Preferred compounds occur when v, w and h are 1.
  • Ro derivatives are ethyl and propyl.
  • Ro is an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro- Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro- Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate
  • R 2 , R 3 are hydrogen atoms, and either X or Y is an alkoxyl or hydroxyl group -ORe, wherein Re is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is an amine group -NR 6 R 7 , wherem Re and R 7 are members of a group consisting of hydrogen and optionally substituted ( -C 15 ) hydrocarbons, or can together form a ring, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfide or thiol group -SR ⁇ 8 , wherein R )7 is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 15 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C Ci5)alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfone or sulfoxide group -S(0) w R,_, wherein Re is a member of a group consisting of hydrogen and optionally substituted (C 1 - 5 ) hydrocarbons, w is an integer from 1 to 2, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 15 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a sulfonamide group -S0 2 NR6R 7 , wherein R ⁇ ; and R 7 are members of a group consisting of hydrogen and optionally substituted ( -Cis) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted ( -C ⁇ alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a phosphonate group -PO(OR 6 ) 2 , wherein R 6 is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 15 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a carboxylate or ester group -CO ⁇ R ⁇ , wherein Rs is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 15 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a carboxylate or ester group -COR.
  • R 6 is a member of a group consisting of hydrogen and optionally substituted (C 1 -C1 5 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic
  • Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a halogen group -F, -CI or -Br, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is OR), wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 , R 3 are hydrogen atoms, and either X or Y is a substituted or unsubstituted aryl, heteroaryl, arylalkyl, alkylheteroaryl, heterocyclic, saturated and unsaturated ring or ring bearing group -R- 8 , wherein the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic; and Z is ORo, wherem Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 15 )alkyl, arylalkanyl or heteroarylalkyl.
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • Ro derivatives are ethyl and propyl.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • Ro is an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ
  • R 2 or R 3 is a member of a group consisting of optionally substituted ( -C ⁇ alkyl, arylalkanyl or heteroarylalkyl in which the stereogenic center to which the R 2 or R 3 is attached is either of R or S configuration, or is a racemic mixture; and Z is - ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 or R 3 are the (2- methyl)-l -propyl (i.e. isobutyl) group, the benzyl moiety, a 2,3 or 4-pyridylmethylenyl group, a 2 or 3 furylmethylenyl group, a cyclopropylmethylenyl group, and so forth.
  • Ro derivatives are ethyl, propyl, and isobutyl.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • Ro an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ,
  • R 2 or R 3 is a member of a group consisting of optionally substituted (C ⁇ -C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl in which the stereogenic center to which the R 2 or R 3 is attached is either of R or S configuration, or is a racemic mixture; and Z is - ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted ( - C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl.
  • R 2 or R 3 are the (2- methyl)-l -propyl (i.e. isobutyl) group, the benzyl moiety, a 2,3 or 4-pyridylmethylenyl group, a 2 or 3 furylmethylenyl group, a cyclopropylmethylenyl group, and so forth.
  • Ro derivatives are ethyl, propyl, and isobutyl.
  • n is an integer from 1 -6
  • m is an integer from 1 - 6
  • either X or Y is a sulfone or sulfoxide group -S(0) w R 6 , wherein Re is a member of a group consisting of hydrogen and optionally substituted (C 1 -C 15 ) hydrocarbons, w is an integer from 1 to 2, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic.
  • n is an integer from 1 -6
  • m is an integer from 1 - 6
  • either X or Y is a carboxylate or ester group -C0 2 Re, wherein Re is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 15 ) hydrocarbons, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic.
  • n is an integer from 1 -6
  • m is an integer from 1 - 6
  • either X or Y is a halogen group -F, -CI or -Br, where further the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic.
  • n is an integer from 1 -6
  • m is an integer from 1 - 6
  • either X or Y is a substituted or unsubstituted aryl, heteroaryl, arylalkyl, alkylheteroaryl, heterocyclic, saturated and unsaturated ring or ring bearing group -Ris, wherein the stereogenic carbon bearing X and Y can be either in R or S configuration, or racemic.
  • R t is optionally substituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings. Also contained are NHR 1 9, NR ⁇ 9 R 20 ,
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • Preferred compounds occur when v, w and h are 1.
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • Ro derivatives are ethyl and propyl.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • R derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • Ro is an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ
  • W is an integer from 0 to 14
  • u is an integer from 0 to 6
  • v is an integer from 0 to 6
  • h is an integer from 0 to 6
  • i is an integer from 0 to 6.
  • Preferred compounds occur when v, w and h are 1.
  • Ro derivatives are ethyl and propyl.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • Ro derivatives are ethyl, propyl, 2-(N,N'-dimethylamino)ethyl- (and acid salts thereof), and aryl or heteroaryl rings.
  • R is an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro- Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro- Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate
  • R and Ri are -CH 2 OCOR-t, and the other is hydrogen;
  • Z is ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C C ⁇ 5 )alkyl, arylalkanyl or heteroarylalkyl; and Rt is H, heterosubstituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or unsubstituted normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroar
  • R t of R is -(CH 2 ) g NH 2 - HCI or other acid salts
  • G is an integer from 0 to 14
  • t of R t is -CH 3 .
  • R t of R is -CH 2 (CH 2 ) w COOH (and salts thereof); and R of R ! is -CH 3 .
  • u is an integer from 0 to 6 and v is an integer from 0 to 6.
  • u and v together equal 7, for azelaic acid.
  • Ro derivatives are ethyl and propyl.
  • Ro is an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein.
  • an antioxidant such as ascorbic acid (Vitamin C), retinol (Pro-Vitamin A), vitamin E (the various tocopherols and tocophatrienes), vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t- butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ
  • R 2 o or R 2 ⁇ must be a -NO, or both R 2 o and R 2i can be -NO.
  • R 20 -NO or -COR,, or -CH 2 OCOR t or -CH(R j )OCOR t or H.
  • R 21 -NO or -COR 4 , or -CH 2 OCOR t or -CH(R j )OCOR t or H.
  • Z can be OH, OR,, NHR,, NHOH, NHNR 22 R 23 , NHCOR,,
  • R j can be H, optionally substituted alkyl, branched alkyl, cycloalkyl, bi and tricycloalkyl and bi and tricycloalkenyl, alkenyl, allenyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, alkynyl, aryl, arylmethylenyl, arylethylenyl, heteroalkyl, heterocyclic, heteroaromatic, alkylheterocyclic, alkylheteroaryl.
  • R j can be an ether OR 5 ; disubsituted amine NReR 7 ; ester COOR 8 ; aldehyde CHO; mono, di or unsubsituted amide CONR 9 R 10 ; ketone CORn; sulfide R 30 S-; sulfoxide R 3 ⁇ SO-; or sulfone R 32 SO 2 -.
  • an optional substituent can also be selected from the above group as well as the following: alcohol; mono, or unsubsituted amine NReR 7 ; formate OCHO; formamide NRoCHO; acyl ester OCOR ⁇ 2 ; acyl carbonate OCOOR 13 ; acyl carbamate OCONR ⁇ 4 R ⁇ 5 ; acyl urea NR ⁇ 6 CONR ⁇ 7 R 18 ; halides F, CI, Br, or I; nitro N0 2 ; nitroso, NO; hydrazide R 19 NNR 20 R 2.
  • acyl hydrazide R 22 CONR 23 NR 24 R 25 ; diacyl hydrazide R 26 CONR 27 R 28 COR 29 ; sulfonamide R 33 R 34 NS0 2 -; sulfonamidyl R 35 NS0 2 R 36 ; disulfide R 37 SS-; acyl thioyl R 38 C0S-; thioyl carbonate R 39 OCOS-; thioyl carbamate K t oR t.
  • the optional substituent may be attached withR or S stereochemistry, or may be racemic. hi other instances, the substituent may not be chiral.
  • antioxidant molecules linked through ester or other carbonyl bonds e.g. ascorbic acid, retinol, vitamin E, vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t-butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein);
  • antioxidant molecules linked through ester or other carbonyl bonds e.g. ascorbic acid, retinol, vitamin E, vitamin D, hydroquinone, di(t-butylated)hydroxytoluene BHT, t-butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, que
  • Ro and R 22 - s 4 optionally substituted C1-C20 alkyl, aryl, alkylaryl, alkenyl, heterocyclic, heteroaryl and alkylheteroaryl.
  • Z is ORo, wherein R, is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 2 o)alkyl, arylalkanyl or heteroarylalkyl and various polyethylene glycol polymers.
  • R t is H, heterosubstituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or unsubstituted normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted .aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted alkylheteroaryl rings. Also contained are NHR 2 6, NR 2 6 2 7. OR 26 . SR 26 .
  • R 2 0 or R 2 ⁇ must be a -NO, or both R 20 and R 2 ⁇ can be -NO.
  • R 20 -NO or -COR t , or -CH 2 OCOR t .or -CH(R)OCOR t or H.
  • R 21 -NO or -COR,, or -CH 2 OCOR- t .or -CH(R j )OCOR t or H.
  • Z OH, ORo, NHRo, NHOH, NHNR 22 R 23 , NHCORQ, NH(CH 2 ) n NR 2 R 2 5.
  • n 0 - 8.
  • R j can be H, optionally substituted alkyl, branched alkyl, cycloalkyl, bi and tricycloalkyl and bi and tricycloalkenyl, alkenyl, allenyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, alkynyl, aryl, arylmethylenyl, arylethylenyl, heteroalkyl, heterocyclic, heteroaromatic, alkylheterocyclic, alkylheteroaryl.
  • Rj can be an ether OR 5 ; disubsituted amine NR ⁇ R?; ester COOR s ; aldehyde CHO; mono, di or unsubsituted amide CONR 9 R ⁇ 0 ; ketone COR n ; sulfide R30S-; sulfoxide R3 1 SO-; or sulfone R 32 S0 2 -.
  • an optional substituent can also be selected from the above group as well as the following: alcohol; mono, or unsubsituted amine NR 6 R 7 ; formate OCHO; formamide NRoCHO; acyl ester OCOR ⁇ 2 ; acyl carbonate OCOOR ⁇ 3 ; acyl carbamate OCONR 14 R 15 ; acyl urea NRieCONR ⁇ Ris; halides F, CI, Br, or I; nitro NO 2 ; nitroso, NO; hydrazide R 19 NNR 20 R 2 -; acyl hydrazide R 22 CONR23NR2 4 R25; diacyl hydrazide R 26 CONR 27 NR 2 8COR 29 ; sulfonamide R 33 R 34 NS0 2 -; sulfonamidyl R 35 NS0 2 R 36 ; disulfide R37SS-; acyl thioyl R 38 COS-
  • the optional substituent may be attached withR or S stereochemistry, or may be racemic. In other instances, the substituent may not be chiral.
  • These optional groups can contain antioxidant molecules linked through ester or other carbonyl bonds (e.g. ascorbic acid, retinol, vitamin E, vitamin D, hydroquinone, di(t-butylated)hydroxytoluene
  • BHT t-butylatedhydroxyanisole BHA, t-butylhydroquinone TBHQ, propyl gallate, reduced coenzyme-Q, flavones and isoflavones such as apigenin, quercetin, genistein, and daidzein);
  • Ro and R 20 - R 54 optionally substituted C1-C20 alkyl, aryl, alkylaryl, alkenyl, heterocyclic, heteroaryl and alkylheteroaryl.
  • Z is OR, wherein Ro is a member of a group consisting of hydrogen and optionally substituted ( -C ⁇ alkyl, arylalkanyl or heteroarylalkyl and various polyethylene glycol polymers.
  • R t is H, heterosubstituted (alcohols, ketones, carboxylates, sulfides, sulfoxides, sulfones, sulfonamides, amines, amides, urethanes, thiourethanes, ureas, carbonates, acetals, ketals, etc.) or unsubstituted normal, branched, cyclic or substituted cyclic hydrocarbons from C1-C20; aryl ring, substituted aryl ring; alkylaryl rings and substituted arylalkyl rings; heterocyclic rings and substituted heterocyclic rings; heteroaromatic rings and substituted heteroaromatic rings; alkylheteroaryl rings and substituted al
  • n is an integer from 0 - 8
  • Z is -ORo, wherein Ro is a member of a group consisting of hydrogen and optionally substituted (C ⁇ -C 15 )alkyl, arylalkanyl or heteroarylalkyl.
  • Inflammatory skin diseases including psoriasis vulgaris, p. guttata, p. discoidea, p. anthropica, p. universalis, eczema
  • Acne (all forms, including a. vulgaris, a. rosacea, a. inversa, cystic acne)
  • Warts verrucae (including common warts, anogenital (venereal) warts, viral warts including human papilloma virus (HPV) infections, conjunctival warts, oral/buccal warts)
  • verrucae including common warts, anogenital (venereal) warts, viral warts including human papilloma virus (HPV) infections, conjunctival warts, oral/buccal warts
  • Keratoses such as seborrheic keratosis, senile keratosis, actinic keratosis, photo-induced keratosis, skin aging, thinning skin, dry skin, wrinkle formation, keratosis follicularis
  • Atopic skin diseases including atopic dermatitis, atopic eczema, allergic dermatitis, chemical or irritant dermatitis), allergic dermatoses
  • Sun-damaged skin dry skin, chapped skin, wrinkled skin, aging skin, sagging skin, rough skin, weathered skin, inflammed skin, reddened skin, psoriasis, keratitis, hidradenitis, ichthyosis, acne, rosacea, warts, verrucae and related to human papilloma virus infection, seborrheic keratosis, senile keratosis, actinic keratosis, photo-induced keratosis, skin aging, thinning skin, dry skin, wrinkle formation, photo-induced skin aging, keloids, lichen planus, comprismg a compound of this, or a cosmetically acceptable salt thereof.
  • Acute and chronic dermatitides inflammation of the skin
  • atopic dermatitis allergic dermatitis, contact dermatitis, cosmetic dermatitis, chemical dermatitis, seborrheic dermatitis, atopic dermatitis, seborrheic dermatitis, solar dermatitis, acute and chronic eczema, atopic eczema, solar dermatitis, acute and chronic eczema, diaper rash, sunburn.
  • TABLE III Examples of diseases of various organ systems preventable or treatable using compounds described in this invention
  • vasculo-occlusive diseases including atherosclerosis, arteritis, endarteritis, endocarditis, myocarditis, arterial plaque (fibrous cap) rupture, thrombosis, restenosis after any invasive vascular procedures; acute coronary syndromes such as unstable angina, myocardial infarction, myocardial ischemia and other ischemic cardiomyopathies, non-ischemic cardiomyopathies, post-myocardial infarction cardiomyopathy and myocardial fibrosis, drug-induced cardiomyopathy.
  • Endocrine Obesity type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, impaired glucose tolerance, Gushing' s syndrome (e.g. secondary to chronic glucocorticoid therapy), polycystic ovarian syndrome, osteoporosis, osteopenia, accelerated aging of tissues and organs, e.g. Werner's syndrome.
  • Urogenital Prostatitis endometritis, endometriosis, benign prostatic hypertrophy, leiomyoma, polycystic kidney disease (e.g. autosomal dominant PKD), acute tubular necrosis, nephrotic syndrome, diabetic nephropathy, glomerulonephritis.
  • PKD polycystic kidney disease
  • Pulmonary Asthma Pulmonary Asthma, chronic obstructive pulmonary disease (COPD), reactive airway disease, pulmonary fibrosis, pulmonary hypertension.
  • COPD chronic obstructive pulmonary disease
  • alcohol-induced e.g. ethanol
  • drug-induced e.g. Tylenol
  • toxin- induced e.g. mushroom poisoning
  • Neurologic/ Migraine headaches vascular headaches, Alzheimer's disease, diseases psychiatric associated cognitive dysfunction, secondary dementias and degenerative CNS diseases (e.g. diseases associated HIV, slow virus or prion infection) associated with viruses and prions (e.g. Parkinson's disease, amyotropic lateral sclerosis, multiple sclerosis, Guillain-Barre; Pain disorders including algesia, hyperalgesia, acute and chronic pain, allodynia; Primary and secondary encephalitis and encephalomyelitis (e.g. autoimmune encephalomyelitis, allergic encephalomyelitis); Primary and secondary neuritis, autoimmune neuritis
  • autoimmune diseases e.g. myesthenia gravis, Eaton-Lambert syndrome
  • congenital and secondary ataxias TABLE IV examples of viral infections and related pathologies preventable or treatable according to the methods of this invention
  • HPV Cervical and anogenital cancers including verrucae, condyloma or condyloma acuminata, related non- neoplastic (e.g., keratitis, conjunctivitis) pre-neoplastic and neoplastic (e.g., conjunctival epithelial neoplasms) diseases of the eye.
  • non- neoplastic e.g., keratitis, conjunctivitis
  • pre-neoplastic and neoplastic e.g., conjunctival epithelial neoplasms
  • HAV HAV
  • HBV HCV
  • Hepatitis hepatocellular carcinoma, lymphoma.
  • CMV Hepatitis, retinitis, meningitis.
  • HSV VSV Related mucocutaneous, oropharyngeal and genital diseases, related skin and respiratory infections, varicella-zoster, chicken pox, herpes zoster, post-herpetic neuralgia, conjunctivitis, keratoconjunctivitis, keratitis.
  • HHV Exanthem subitum infectious mononucleosis. EBV Infectious mononucleosis, chronic fatigue syndrome, lymphoma, conjunctivitis, keratitis, and related eye infections.
  • Adenoviruses Upper and lower respiratory tract infections, pneumonia, conjunctivitis.
  • PMV Mumps and related manifestations e.g., conjunctivitis.
  • Coxsackie viruses Conjunctivitis, diabetes mellitus, respiratory infections.
  • Influenza viruses Upper and lower respiratory tract infections, pneumonia.
  • HIV Human Immunodeficiency Virus
  • HPV Human Papilloma Virus
  • HAV Hepatitis A Virus
  • HBV Hepatitis B Virus
  • HAV Hepatitis C Virus
  • CMV Cytomegalovirus
  • HSV Herpes Simplex Virus (Types I & II)
  • HHV Human Herpes Virus
  • EBV Epstein-Barr Virus
  • RSV Respiratory Syncytial Virus
  • VZV Varicella-Zoster Virus
  • PMV Paramyxovirus
  • MV Measles (Rubeola) Virus
  • RV Rubella Virus
  • Table V HIV related infections and diseases preventable or treatable using compounds described in this invention
  • Immunologic AIDS primary HIV infection. Dermatological Anogenital cancers including rectal and cervical cancer, Kaposi's sarcoma, atopic dermatitis, squamous cell carcinoma, hairy leukoplakia, molluscum contagiosum, warts (HPV infections), seborrheic dermatitis, psoriasis, xeroderma, HSV and varicella-zoster infections.
  • Dermatological Anogenital cancers including rectal and cervical cancer, Kaposi's sarcoma, atopic dermatitis, squamous cell carcinoma, hairy leukoplakia, molluscum contagiosum, warts (HPV infections), seborrheic dermatitis, psoriasis, xeroderma, HSV and varicella-zoster infections.
  • Hematologic Non-Hodgkin's lymphoma B cell lymphoma, anemia, neutropenia, thrombocytopenia.
  • Ophthalmic Conjunctivitis keratitis, keratoconjunctivitis, uveitis, retinitis, chorioretinitis, CMV retinitis, iridocyclitis, vitreitis, choroiditis, papilledema, Kaposi's sarcoma, lymphoma, ocular palsies, conjunctival warts, pre-neoplastic and neoplastic diseases of the eye.
  • Neurologic Dementia viral meningitis, viral encephalitis, HIV encephalopathy, progressive multifocal leukoencephalopathy, CNS lymphoma, peripheral and autonomic neuropathies.
  • Psychiatric Dysphoric mood disorders depression, depression associated with chronic diseases and medications, bipolar disorder, anxiety disorders, chronic fatigue syndrome, chronic pain, psychoses, substance abuse disorders and drug addiction.
  • Conjunctivitis Acute allergic conjunctivitis (e.g. drug-related inflammation, hypersensitivity reactions), chronic (vernal) conjunctivitis, contact lens- associated conjunctivitis, e.g. giant papillary conjunctivitis, conjunctival ulceration, including ulceration associated with mucous membrane, conjunctival warts, follicular, hemorrhagic or catarrhal conjunctivitis, viral conjunctivitis - all viral etiologies.
  • conjunctivitis e.g. drug-related inflammation, hypersensitivity reactions
  • chronic (vernal) conjunctivitis e.g. contact lens- associated conjunctivitis
  • contact lens- associated conjunctivitis e.g. giant papillary conjunctivitis
  • conjunctival ulceration including ulceration associated with mucous membrane, conjunctival warts, follicular, hemorrhagic or
  • Blepharitis Inflammatory etiologies e.g. blepharitis secondary to rosacea. Keratitis All etiologies
  • Keratoconjunctivitis All etiologies Ophthalmic fibrosis Steven's-Johnson syndrome with progressive fibrosis and scarring, cicatrization and symblepharon.
  • Corneal injury Corneal abrasion or ulceration (e.g. contact lens-related injury), or corneal injury of any etiology*.
  • Vitreitis retinitis Congenital retinitis, retinitis pigmentosa Infectious retinitis Viral (e.g. herpes, cytomegalovirus, HIV), tuberculous, syphititic, fungal (e.g. histoplasmosis)
  • Chorioretinopathies Chorioretinitis, choroiditis, vitreitis, Retinopathies Diabetic retinopathy, hypertensive retinopathy Maculopathies Age-related-macular degeneration, white dot syndromes Cataract Related to aging, diabetes, collagen vascular diseases Ocular palsies
  • ophthalmic diseases treatable according to the methods of this invention include diseases induced or caused by physical agents (e.g. UV radiation), chemical agents (e.g. acids, caustic solvents) immunological etiologies (e.g. collagen vascular diseases, auto-immune, T lymphocyte-related), infectious agents such as viruses (HSV, CMV, HIV), mycoplasma, tuberculosis, syphilis, fungae (liistoplasmosis) TABLE VII: Ophthalmic diseases preventable or treatable using compounds described in this invention (cont'd)
  • physical agents e.g. UV radiation
  • chemical agents e.g. acids, caustic solvents
  • immunological etiologies e.g. collagen vascular diseases, auto-immune, T lymphocyte-related
  • infectious agents such as viruses (HSV, CMV, HIV), mycoplasma, tuberculosis, syphilis, fungae (liistoplasmosis)
  • Dry Eye Syndrome Hypofunction of the lacrimal gland as in, e.g. Sj ⁇ gren's Syndrome, progressive systemic sclerosis, sarcoidosis, leukemia, lymphyoma, amyloidosis, hemochromatosis; Infection, e.g. mumps; Injury, e.g. surgical removal of lacrimal gland, irradiation, chemical burn; Medications, e.g. antihistamines, antimuscarinics, general anesthetics, - adrenergic blockers; Congenital causes; Neurogenic, e.g. facial nerve palsy.
  • Avitaminosis A Stevens-Johnson syndrome, ocular pemphigoid, chronic conjuncitivitis (e.g. trachoma), chemical burns, drugs and medications
  • Defective Spreading of Team Film Caused by: eyelid abnormalities, including defects, colboma; ectropion or entropion, keratinization of lid margin, decreased or absent blinking secondary to: neurologic disorders, hyperthyroidism, contact lens, drugs and medications, herpes simplex keratitis, leprosy, conjunctival abnormalities, pterygium, symblepharon, proptosis
  • Macular disorders All etiologies and manifestations, including age-related macular degeneration, exudative macular degeneration, atrophic macular degeneration, crystalline retinopathies, retinal toxicosis of systemic medications, idiopathic central serous choroidiopathy, macular edema
  • Retinovascular Retinopathy vasculo-occlusive r., ischemic r., idiopathic r., hypertensive r., diseases and proliferative v., diabetic r., vitteoretinopathy, vasculopathies associated with retinopathies: telangiectasias or aneurysms, retinopathies associated with lupus erythematosus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, uveoretinitis or diabetes mellitus, glaucomatous retinopathies
  • Glaucoma All etiologies and manifestations, including primary and secondary open- angle glaucoma, angle-closure glaucoma, glaucoma associated with intraocular inflammation, elevated intraocular pressure associated with acute glaucoma, steroid-induced glaucoma, glaucoma associated with intraocular hemorrhage, pseudoexfoliative syndrome, glaucomatous optic neuropathy and other degenerative changes (e.g. retinopathy) associated with glaucoma
  • Cataract All etiologies and manifestations, including age-related (UV radiation) cataract, cataract associated with systemic diseases such as collagen vascular disease, diabetes mellitus, Wilson's disease
  • X-linked recessive pigmented retinopathies e.g. choroideremia
  • Autosomal recessive pigmented retinopathies e.g. diabetes mellitus, mannosidoses, mucopolysccharidoses, Batten's d., Refsum's d., Usher syndrome - X-linked recessive pigmented retinopathies, e.g. Hunter syndrome
  • Wounds caused by chemical or physical agents e.g. ulcers caused by caustic or erosive chemicals, pressure sores, etc.
  • Wounds associated with disease states e.g. diabetic ulcers etc. Wounds in diseased tissues or organs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'administration à un homme ou un animal nécessitant un traitement, d'une quantité efficace d'un dérivé d'acide lipoïque antioxydant et/ou les stéréoisomères, les solvates ou les sels pharmaceutiquement acceptables de ce dernier, pour traiter ou prévenir l'inflammation pathologique, les maladies prolifératives, dégénératives, métaboliques ou néovasculaires, ou encore les maladies virales ou à prions. Un autre aspect de l'invention concerne l'utilisation de composés selon l'invention pour améliorer les conditions nutritionnelles ou cosmétiques liées au vieillissement de la peau (rides et peau flétrie) et d'autres systèmes d'organe, la détérioration des organes liée à la maladie (par exemple, la dysérection) et les toxines environnementales. La présente invention concerne également des méthodes de synthèse de nouveaux dérivés d'acide lipoïque antioxydant et leur utilisation dans la prévention et le traitement de maladies ou de conditions provoquées par le stress oxydatif et d'autres conditions induites par les radicaux libres. Les compositions selon la présente invention sont utilisées pour protéger la peau des dommages provoqués par le rayonnement ultraviolet et le dessèchement et pour conférer une meilleure sensation à la peau par desquamation, nettoyage et éclaircissement de la peau. Pour un usage cosmétique, ces compositions sont incorporées dans des produits antisolaires, des savons, des lotions hydratantes, des lotions tonifiantes et d'autres produits de soin de la peau. Les compositions décrites dans cette invention augmentent la viabilité des cellules, activent la protection des cellules et réduisent la production de médiateurs inflammatoires dans les cellules et les tissus, elles peuvent être administrées par application topique, par les muqueuses, par voie sous-cutanée, orale, intraveineuse ou intramusculaire.
PCT/US2002/010761 2002-04-03 2002-04-03 Analogues d'acide lipoique utiles en tant que provitamines et antioxydants WO2003084532A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002254546A AU2002254546A1 (en) 2002-04-03 2002-04-03 Lipoic acid analogs useful as provitamins and antioxidants
PCT/US2002/010761 WO2003084532A1 (fr) 2002-04-03 2002-04-03 Analogues d'acide lipoique utiles en tant que provitamines et antioxydants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/010761 WO2003084532A1 (fr) 2002-04-03 2002-04-03 Analogues d'acide lipoique utiles en tant que provitamines et antioxydants

Publications (1)

Publication Number Publication Date
WO2003084532A1 true WO2003084532A1 (fr) 2003-10-16

Family

ID=28789625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010761 WO2003084532A1 (fr) 2002-04-03 2002-04-03 Analogues d'acide lipoique utiles en tant que provitamines et antioxydants

Country Status (2)

Country Link
AU (1) AU2002254546A1 (fr)
WO (1) WO2003084532A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2415137A (en) * 2004-06-18 2005-12-21 Univ Reading Lipoic acid derivatives for the treatment of atherosclerosis and arthritis
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
JP2009508810A (ja) * 2005-08-04 2009-03-05 エクスタルマ・アーゲー Ｎｏ供与体およびジチオランを含む組成物ならびに性機能の改善のためのそれらの使用
ITMI20091375A1 (it) * 2009-07-30 2011-01-31 Difass S A Composizione comprendente acido alfa-lipoico per il trattamento del dolore pelvico
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
CN102395560A (zh) * 2009-02-17 2012-03-28 因瓦斯科医疗有限公司 包括一氧化氮的二氢硫辛酸衍生物及其治疗应用
US8147816B2 (en) 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8410162B2 (en) 2009-06-15 2013-04-02 Encore Health Llc Choline esters
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8795706B2 (en) 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
US9161931B2 (en) 2008-03-05 2015-10-20 Encore Health, Llc Dithiol compounds and treatment of presbyopia using said compounds
CN106905478A (zh) * 2017-04-19 2017-06-30 贵州大学 一种α‑硫辛酸分子印迹聚合物及其制备方法
US20170209413A1 (en) * 2016-01-26 2017-07-27 Joseph WREEN Use of asparagusic acid and derivatives thereof to treat symptoms and disorders of neurological disease
WO2017160269A1 (fr) * 2016-03-14 2017-09-21 Yu Ruey J Acide aminé ou peptide n-lipoïque, dérivés et leurs utilisations
CN108366934A (zh) * 2015-12-18 2018-08-03 莱雅公司 在施加期间具有颜色转变的组合物
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
US11426381B2 (en) 2014-03-03 2022-08-30 Novartis Ag Lipoic acid choline ester compositions and methods of use
WO2024026200A1 (fr) * 2022-07-27 2024-02-01 Redox Bioscience LLC Méthodes et composés pour le traitement de la colite ulcéreuse, du lupus érythémateux disséminé, du sepsis et du syndrome post-sepsis
US11986460B2 (en) 2018-11-26 2024-05-21 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
WO2024209214A1 (fr) * 2023-04-06 2024-10-10 Elixa Mediscience Ltd Promédicaments d'acides alpha lipoïques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
US5728735A (en) * 1989-11-09 1998-03-17 Asta Pharma Aktiengesellschaft Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient
US5948810A (en) * 1993-12-21 1999-09-07 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728735A (en) * 1989-11-09 1998-03-17 Asta Pharma Aktiengesellschaft Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient
US5948810A (en) * 1993-12-21 1999-09-07 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US9567314B2 (en) 2000-08-16 2017-02-14 Encore Health Llc Dithiol compounds, derivatives, and uses therefor
US9284305B2 (en) 2000-08-16 2016-03-15 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
US10039743B2 (en) 2000-08-16 2018-08-07 Novartis Ag Method of treating presbyopia using dithiol compounds and their derivatives
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US9204996B2 (en) 2000-08-16 2015-12-08 Encore Health, Llc Presbyopia treatment by lens alteration
US8147816B2 (en) 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8795706B2 (en) 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
US8747829B2 (en) 2000-08-16 2014-06-10 Encore Health, Llc Presbyopia treatment by lens alteration of disulfide bonds and reduction
GB2415137B (en) * 2004-06-18 2009-04-29 Univ Reading Lipoic acid derivatives for the treatment of atherosclerosis and arthritis
GB2415137A (en) * 2004-06-18 2005-12-21 Univ Reading Lipoic acid derivatives for the treatment of atherosclerosis and arthritis
JP2013136616A (ja) * 2005-08-04 2013-07-11 Encrypta Gmbh Ｎｏ供与体およびジチオランを含む組成物ならびに性機能の改善のためのそれらの使用
CN102670591B (zh) * 2005-08-04 2014-08-06 英柯瑞普塔有限公司 包含一氧化氮供体和二硫戊环的组合物及其在制备性功能改善的药物中的用途
US9107889B2 (en) 2005-08-04 2015-08-18 Encrypta Gmbh Compositions comprising an NO donor and a dithiolane and their use for improvement of sexual function
JP2009508810A (ja) * 2005-08-04 2009-03-05 エクスタルマ・アーゲー Ｎｏ供与体およびジチオランを含む組成物ならびに性機能の改善のためのそれらの使用
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US9517225B2 (en) 2008-03-05 2016-12-13 Encore Health, Llc Low dose lipoic acid pharmaceutical compositions and methods
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
US9161931B2 (en) 2008-03-05 2015-10-20 Encore Health, Llc Dithiol compounds and treatment of presbyopia using said compounds
CN102395560A (zh) * 2009-02-17 2012-03-28 因瓦斯科医疗有限公司 包括一氧化氮的二氢硫辛酸衍生物及其治疗应用
US8410162B2 (en) 2009-06-15 2013-04-02 Encore Health Llc Choline esters
US9326970B2 (en) 2009-06-15 2016-05-03 Encore Health Llc Choline esters
ITMI20091375A1 (it) * 2009-07-30 2011-01-31 Difass S A Composizione comprendente acido alfa-lipoico per il trattamento del dolore pelvico
US11426381B2 (en) 2014-03-03 2022-08-30 Novartis Ag Lipoic acid choline ester compositions and methods of use
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
KR102172112B1 (ko) 2015-12-18 2020-11-02 로레알 도포 중 색변환을 갖는 조성물
CN108366934A (zh) * 2015-12-18 2018-08-03 莱雅公司 在施加期间具有颜色转变的组合物
KR20180094865A (ko) * 2015-12-18 2018-08-24 로레알 도포 중 색변환을 갖는 조성물
US20170209413A1 (en) * 2016-01-26 2017-07-27 Joseph WREEN Use of asparagusic acid and derivatives thereof to treat symptoms and disorders of neurological disease
WO2017160269A1 (fr) * 2016-03-14 2017-09-21 Yu Ruey J Acide aminé ou peptide n-lipoïque, dérivés et leurs utilisations
RU2737377C2 (ru) * 2016-03-14 2020-11-27 Неострата Компани, Инк. N-липоевая аминокислота или пептид, производные и их применение
US11155531B2 (en) 2016-03-14 2021-10-26 Neostrata Company, Inc. N-lipoic-amino acid or peptide, derivatives and their uses
CN106905478A (zh) * 2017-04-19 2017-06-30 贵州大学 一种α‑硫辛酸分子印迹聚合物及其制备方法
US11986460B2 (en) 2018-11-26 2024-05-21 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
WO2024026200A1 (fr) * 2022-07-27 2024-02-01 Redox Bioscience LLC Méthodes et composés pour le traitement de la colite ulcéreuse, du lupus érythémateux disséminé, du sepsis et du syndrome post-sepsis
WO2024209214A1 (fr) * 2023-04-06 2024-10-10 Elixa Mediscience Ltd Promédicaments d'acides alpha lipoïques

Also Published As

Publication number Publication date
AU2002254546A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
US20020048798A1 (en) Novel antioxidants
WO2003084532A1 (fr) Analogues d'acide lipoique utiles en tant que provitamines et antioxydants
EP1673338B1 (fr) Composes derives d'acides gras preparation et utilisations
EP1120407B1 (fr) Dérivés de la cystine
US6541473B2 (en) Resorcinol derivatives
FR2580277A1 (fr) Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant
EP0232199A2 (fr) Composés benzamido aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique
US20030185865A1 (en) Cosmetic or dermatological preparations for avoiding skin damage by peroxide
FR2719041A1 (fr) Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
CA2147808C (fr) Composes bi-aromatiques acetylenes a groupement adamantyle, compositions pharmaceutiques et cosmetiques les contenant et utilisations
EP1044966B1 (fr) Composés (poly)thia-alcynoiques et leurs dérivés, compositions les comprenant et leur utilisation
EP2191816B1 (fr) Procédé de dépigmentation des matières kératiniques à l'aide de composés dithiolanes.
CH671577A5 (fr)
FR2713640A1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
EP0179697B1 (fr) Nouveaux dérivés de l'acide rétinoique, leur procédé de préparation et compositions médicamenteuse et cosmétique les contenant
EP1296946B1 (fr) Composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA1265134A (fr) Hydroxy-1 acyloxy-8 acyl-10 anthrones, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
CH667452A5 (fr) Derives substitues en 1 du methoxy-4 trimethyl-2,3,6 benzene, leur procede de preparation et compositions medicamenteuse et cosmetique les contenant.
FR2877666A1 (fr) Compositions, notamment cosmetiques, comprenant une benzoisothiazolone
WO2013154832A2 (fr) 2-pyrimidine thioesters et thiocarbonates utilisés en tant qu'agents éclaircissant la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP